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Cyclosporine is a commonly used immunosuppressive drug in dogs, but dosing is
often empirical and based primarily on clinical response. Pharmacokinetic monitoring of
blood drug concentrations can be performed, but target blood concentrations for various
disease states in dogs are not well described. Pharmacodynamic assays measuring the
effects of cyclosporine on target cells are being used to evaluate immunosuppressive
effectiveness in humans, but have been minimally explored in veterinary medicine. This
dissertation describes the development of pharmacodynamic assays for measuring the
effects of cyclosporine on canine T cell cytokine production and surface antigen
expression. Incubation with cyclosporine in vitro caused significant suppression of
activated T cell production of interleukin-2 (IL-2), IL-4, interferon-gamma (IFN-gamma),
CD25, and CD95 measured in peripheral blood mononuclear cells using flow cytometry.
IL-2 and IFN-gamma were then evaluated using flow cytometry and quantitative reverse
transcription polymerase chain reaction (qRT-PCR) in whole blood incubated with
cyclosporine and dexamethasone in vitro. Cyclosporine caused concentration-dependent
inhibition of both cytokines, and a greater degree of suppression was noted with qRTPCR than flow cytometry. Dexamethasone caused concentration-dependent inhibition of

IFN-gamma with both methods, but IL-2 reduction was only significant for qRT-PCR.
Both methods were then used to evaluate IL-2 and IFN-gamma after administration of
high dose oral cyclosporine to dogs. Both qRT-PCR and flow cytometry identified
marked cytokine suppression after cyclosporine dosing, but qRT-PCR was uniformly
suppressed across the 12-hour dosing interval, while flow cytometry results were
significantly higher at trough blood drug concentrations than at peak blood
concentrations and subsequent post-dosing time points. Both flow cytometry and qRTPCR are valid methods for evaluation of T cell cytokine expression in dogs. Further
study at lower drug doses is needed to correlate pharmacodynamic results with
pharmacokinetic drug concentrations, and to confirm the best method for cytokine
monitoring. Studies in clinic patients are also needed to determine the level of cytokine
suppression associated with clinical effectiveness in different disease states.
Pharmacodynamic evaluation of cyclosporine’s effects shows promise, and may allow for
more individualized dosing of cyclosporine in dogs.
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INTRODUCTION
Background
Cyclosporine is an important immunosuppressive drug, originally pioneered for
human transplantation, but since employed for a variety of inflammatory and immunemediated diseases in both human and veterinary medicine. In veterinary medicine,
cyclosporine is approved for the treatment of atopic dermatitis in dogs, and for
inflammatory skin diseases in cats, at a relatively low dose of five and seven mg/kg/day
in dogs and cats, respectively.1,2 Higher extralabel doses (up to 20 mg/kg/day) are used
for transplantation and in the treatment of immune-mediated diseases such as
inflammatory bowel disease, immune-mediated thrombocytopenia, and immunemediated hemolytic anemia.3 Cyclosporine decreases adaptive immune responses by
reducing cytokine release from T cells. Specifically, cyclosporine inhibits calcineurin,
which is then unable to dephosphorylate nuclear factor of activated T cells (NFAT), a
transcription factor normally involved in the production of pro-inflammatory cytokines,
including interleukin 2 (IL-2), needed for the proliferation of T cells.4 Nephrotoxicity is
the most significant adverse event in human medicine,5 while gastrointestinal adverse
effects predominate in veterinary medicine.6 In both humans and companion animals, a
primary difficulty in cyclosporine therapy is variability in patient response, with an
associated need for individualized therapy.
1

Cyclosporine is a large hydrophobic molecule, and the first approved human
formulation of the drug, Sandimmune®, suffered from poor bioavailability and highly
variable absorption.7 Because the drug was used in transplant medicine, it was important
that cyclosporine reach therapeutic levels to help prevent rejection, but that levels not be
so high that the patient experienced nephrotoxicity. Pharmacokinetic monitoring of
trough blood concentrations was used to monitor the cyclosporine concentrations being
achieved in individual patients, but there was poor correlation between blood
concentrations and either transplant rejection or nephrotoxicity.8,9 Pharmacodynamic
measures, evaluating the effect of cyclosporine on the biological target, the T cell, were
also developed, and included measuring T cell IL-2 production and mitogen-induced
lymphocyte proliferation.10-12
Introduction of the microemulsified formulation of cyclosporine, Neoral®, in 1995
reduced interpatient pharmacokinetic variability. Additional pharmacokinetic monitoring
strategies were investigated including area under the curve (AUC) and peak cyclosporine
blood concentration two hours after dosing, both of which showed improved correlation
to patient outcomes compared to trough concentration monitoring.8,13-15 Individual
patients still experienced rejection and nephrotoxicity despite attainment of blood
concentrations considered therapeutic in other patients, however, so pharmacodynamic
assays have continued to be investigated as an alternative method for potentially better
evaluating patient responses to cyclosporine by identifying when lymphocyte suppression
has been adequately achieved.16
The most common pharmacodynamic assays in human medicine include
measuring calcineurin inhibition, activation-related cell surface antigens, cytokines, and
2

lymphocyte proliferation.17-20 Evaluation of NFAT-regulated cytokines, including IL-2,
IL-4, interferon gamma (IFN-γ), and tumor necrosis factor alpha (TNF-α), is one of the
most popular methods of cyclosporine pharmacodynamic monitoring, with cytokines
measured using enzyme-linked immunosorbent assays (ELISAs), flow cytometry, and
quantitative reverse-transcription polymerase chain reaction (qRT-PCR).17,18,21 Serial
monitoring of IL-2 is performed by some groups,20-22 while others evaluate the reduction
in cytokine production at peak cyclosporine blood concentrations relative to trough,
termed “residual gene expression”.18,23 Higher IL-2 levels have been correlated with
higher risk of transplant rejection,12 and lower gene expression has been correlated with a
higher risk of neoplasia and potentially greater immunosuppression than is needed
clinically.24 In human medicine, pharmacodynamic studies are performed in conjunction
with pharmacokinetic studies to help monitor patients after transplantation. No
pharmacodynamic measure is well accepted to improve patient outcome, and none is
standardly performed.
Cyclosporine has a shorter history in veterinary medicine than in human
medicine, having only been approved in 2003 in dogs, and 2011 in cats.1,2 It has been in
extralabel use before and after approval for atopy, however, and there is substantial
clinical experience documenting the lack of nephrotoxicity in companion animals. Given
this, pharmacokinetic monitoring is arguably less essential (since unexpectedly high
concentrations have less major potential adverse reactions), but monitoring is still
performed in cases where achieving a certain blood concentration is important. This
includes the relatively uncommon (in veterinary medicine) scenario of transplantation,2527

as well as life-threatening immune-mediated disease.3 Another common indication for
3

blood cyclosporine measurement is when cyclosporine is paired with another drug, most
often ketoconazole, which impairs the metabolism of cyclosporine and thus allows less
cyclosporine to be given while still attaining target blood concentrations.28-30
Cyclosporine is an expensive drug, and pairing with ketoconazole is most often attempted
for treatment of anal furunculosis (also known as perianal fistulas), when long-term
therapy is needed and patients are often large breed dogs. Target trough concentrations
are most clearly established for transplantation, and little evidence exists to support the
need to monitor trough concentrations for other inflammatory and immune-mediated
conditions. The author is not aware of any published literature investigating peak or
AUC values and their correlations to clinical outcome in veterinary medicine.
Pharmacodynamic evaluation of cyclosporine in veterinary medicine is in its
infancy. Most work has been done in vitro, and has documented decreased production of
cytokines by canine and feline peripheral blood mononuclear cells incubated with
cyclosporine.31,32 Two studies have evaluated the effects of topical ophthalmic
cyclosporine, administered for the treatment of keratoconjunctivitis sicca (dry eye) on the
systemic immune system, with one identifying decreased lymphocyte proliferation,33 and
the other more recent study showing no effect and very low systemic blood cyclosporine
concentrations.34 An additional study investigated cytokine levels in tissue biopsies taken
from the area of anal furunculosis lesions, and showed significantly decreased
intralesional expression of IL-2 after cyclosporine treatment.35 Despite the frequent use
of cyclosporine in clinic patients, very little work has been done to investigate individual
immune responses to oral cyclosporine.
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Variable individual patient immune responses to cyclosporine are strongly
suggested by the reports of animals on cyclosporine developing serious, and sometimes
fatal, infectious diseases while receiving atopy doses not typically considered likely to
cause significant immune suppression.36,37 There are also clinically-apparent differences
in responses to cyclosporine for other immune-mediated diseases, with some animals
showing poor response to therapy despite the use of a dose effective in other patients. It
is likely some of these clinical differences can be attributed to variable lymphocyte
responses to cyclosporine. It is also possible some clinical variability is caused by failure
to achieve sufficient blood concentrations, but again, without well-established target
blood concentrations, this is difficult to definitively determine.
Hypothesis and Chapter Overview
The overall hypothesis of our research laboratory is that a comprehensive panel of
biomarkers of immunosuppression can be used to objectively and accurately establish
target doses and drug concentrations of cyclosporine in the dog. This dissertation
describes the development of a panel of biomarkers, and provides in vitro and in vivo
evidence of their ability to reflect the effects of cyclosporine on canine lymphocytes.
Chapter II gives an overview of the relevant literature pertaining to cyclosporine and its
pharmacokinetic and pharmacodynamic monitoring. Chapter III describes an effort to
identify biomarkers of cyclosporine immunosuppression in dogs, and to develop assays
for their measurement in canine blood samples using flow cytometry. Chapter IV then
evaluates the effects of in vitro cyclosporine and dexamethasone on a biomarker panel
using flow cytometry and a previously validated qRT-PCR assay. In Chapter V, these
biomarkers are then evaluated after oral cyclosporine to assess cyclosporine’s
5

pharmacokinetic/pharmacodynamic relationship with concurrent cyclosporine blood
concentration determination and biomarker measurement using flow cytometry and qRTPCR. Chapter VI summarizes findings and discusses future research directions.
Project Significance
At present, veterinary medicine lacks effective means for monitoring patient
response to cyclosporine. This dissertation describes initial investigations into the
pharmacodynamic evaluation of oral cyclosporine in dogs using both flow cytometry and
qRT-PCR. Since glucocorticoids are often co-administered with cyclosporine, their
effect on the biomarkers is also evaluated.
Veterinary medicine has made tremendous advancements in recent decades. The
American College of Veterinary Internal Medicine was recognized by the American
Veterinary Medical Association in 1980, and since that time specialty medicine has
evolved into a growing industry that has revolutionized the standard of care and ability to
provide quality medicine for companion animals. That said, veterinary medicine still
largely relies on knowledge gleaned from human medicine for pioneering new treatments
and diagnostic modalities. Although this approach is understandable, as a profession
veterinarians must continue to seek opportunities for innovative and original animal
research.
Pharmacodynamic assessment of cyclosporine’s effects is an example of how
human medicine is becoming individualized to tailor treatment plans to the patient.
Despite being increasingly published, however, definitive cyclosporine
pharmacodynamic standards still remain elusive, with several monitoring strategies
suggested by different groups.17,22,23,38 This dissertation describes a pharmacodynamic
6

monitoring strategy for dogs treated with cyclosporine. Much human cyclosporine
pharmacodynamic research involves transplant monitoring, while this is a much smaller
market for veterinary use. There are, however, a multitude of inflammatory and immunemediated conditions in dogs that would benefit from enhanced cyclosporine monitoring
and, significantly, different degrees of immune suppression are needed for these diseases.
Veterinary medicine offers an excellent opportunity to enhance the understanding of
mammalian immune responses to cyclosporine across a wide variety of doses and dosing
intervals. The biomarkers used to evaluate cyclosporine may also be useful to monitor
overall T cell responsiveness and patient response to other immunosuppressive drugs.
Cyclosporine pharmacodynamics is a step towards individualized veterinary medicine,
and is an important area for research with the potential to improve the standard of care for
veterinary patients with inflammatory and immune-mediated diseases.
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LITERATURE REVIEW
Cyclosporine
History
Cyclosporine is an 11 amino acid cyclic polypeptide with a molecular weight of
1203.63 daltons (Da).1 It was originally isolated from a soil sample collected by H.P.
Frey, a Sandoz employee, while vacationing in Norway.2 Compound 24-556, a
metabolite of the soil fungus Tolypocladium inflatum, also known as Beauveria nivea,3-5
was recognized in 1971 for its strong immunosuppressive properties in the absence of
significant cytotoxicity.6-8 Compound 24-556 also lacked the myelotoxicity caused by
azathioprine, the other major non-glucocorticoid immunosuppressive drug in use at the
time.7,8 Stӓhelin and Borel were the primary discoverers of the molecule working in the
Sandoz laboratory in Switzerland, and it was named cyclosporine because it was a
cyclical peptide derived from a spore.5,9
Early issues with cyclosporine included its hydrophobicity, and difficulty in
obtaining sufficient quantities for testing. Cyclosporine showed significant promise as an
immunosuppressive agent, however, in skin transplantation and autoimmune models.2,10
This early in vitro and in vivo work was first published as an abstract in Experientia,11
and was then described by Borel at the 1976 British Society of Immunology meeting in
London.8 Borel’s presentation sparked interest in the drug as an aid to transplant
11

immunosuppression. Early work was done investigating the drug with heart and renal
allografts in rats and rabbits,12-15 and progressed to work involving dogs and pigs.16-18
These studies demonstrated improved graft function and survival, with minimal side
effects.
Calne and White were two of the leaders in the field, and performed the first
human renal cadaveric transplantations with cyclosporine as the sole
immunosuppressant.19,20 Early trials in humans revealed unacceptable renal toxicity and
a high incidence of lymphoma and secondary infections, but this was improved through
cyclosporine dose reduction.10,20,21 Cyclosporine was developed for the human market,
and the first multicenter trial in Europe documented 73% graft survival for patients
receiving cyclosporine alone, versus 53% for steroid and azathioprine-treated controls.22
This information led to formal approval of the drug by the Food and Drug Administration
(FDA) in 1983, and to cyclosporine even being called “the penicillin of
transplantation.”23
Combining cyclosporine with methylprednisolone led to further improvements in
graft survival, up to 88.2% at six months, compared to 53.2% for azathioprine and
steroid-treated controls.24 Cyclosporine was incorporated into protocols for
transplantation of other organs including heart, liver, and pancreas, and
immunosuppressive protocols were further modified to include azathioprine as part of
“triple-therapy” regimens (steroid + azathioprine + cyclosporine).8 More recently,
mycophenolate mofetil, an inhibitor of inosine-5’-monophosphate dehydrogenase
(IMPDH) that decreases lymphocyte proliferation, has often been included as a
replacement for azathioprine.3
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Cyclosporine is also used in veterinary medicine for renal transplantation,25-28 but
is more commonly used for the treatment of a variety of inflammatory and immunemediated diseases. Atopica®, a microemulsified formulation of cyclosporine, was
approved for the control of atopic dermatitis in dogs in 2003.29 A liquid solution,
Atopica® for cats, was approved in 2011 for the control of feline allergic dermatitis,
including military dermatitis, eosinophilic plaques, and self-induced alopecia.30 There is
also an approved topical formulation of cyclosporine, Optimmune®, used for the
management of chronic keratoconjunctivitis sicca and chronic superficial keratitis in
dogs.31 Cyclosporine undergoes frequent extralabel use in dogs and cats for a number of
conditions, including but not limited to the treatment of immune-mediated hemolytic
anemia, inflammatory bowel disease, anal furunculosis (dogs only), and immunemediated skin diseases.32,33
Chemistry and Clinical Pharmacology
Molecule
Cyclosporin A, commonly called cyclosporine, is produced by the 800 kDa
multifunctional enzyme cyclosporin synthetase.34 The cyclosporine molecule is notable
for having a D-amino acid and only hydrogen bonded or methylated amide nitrogens,
which makes it resistant to degradation in the gastrointestinal tract (Figure 1).3,35 Its
chemical formula is C62H111N11O12,1 and chemical designation is [R-[R*,R*-(E)]]-cyclic
(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxyN,4-dimethyl-L-2-amino-6-octenoyl-L-α-amino-butyrylN-methylglycyl-N-methyl-Lleucyl-L-valyl-N-methyl-L-leucyl).36 Cyclosporine is large, lipophilic, and hydrophobic,
and thus formulation has significant effect on bioavailability.
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Figure 2.1

Cyclosporine molecule

Image used courtesy of Yikrazuul.37
Formulations
The original formulation of cyclosporine, Sandimmune®, is an oil and alcohol
solution,38 and is available as a soft gelatin capsule, oral solution, and intravenous
solution.36 According to the prescribing information, the injectable formulation is in a
polyoxyethylated castor oil vehicle, Cremophor® EL,36 which has been associated with
anaphylactic reactions.39,40 The oral liquid is dissolved in an olive oil vehicle, and the
gelatin capsule contains corn oil and linoleoyl macrogolglycerides. Sandimmune®’s
absolute bioavailability is approximately 30%, and the capsule and oral formulations are
bioequivalent.36
A modified microemulsion was approved in July 1995 with the trade name
Neoral®, and has a surfactant, lipophilic and hydrophilic solvents, and ethanol.38 This
formulation comes as a soft gelatin capsule and oral solution and, for both, corn oil14

mono-di-triglycerides, polyoxyl 40 hydrogenated castor oil NF, DL-α-tocopherol and
propylene glycol are inactive ingredients.41 Neoral® forms a microemulsion in an
aqueous environment, and has higher bioavailability (relative bioavailability of 174239% depending on the dose) and dose proportionality, as well as reduced variability in
pharmacokinetics, compared to Sandimmune®.38,42 While for both Sandimmune® and
Neoral® the respective oral solutions and capsules are bioequivalent, the two formulations
are not bioequivalent.36,41 The veterinary approved product Atopica® is also the
microemulsified (modified) cyclosporine. Human generic formulations are available for
Neoral® and Sandimmune®.
Absorption
Cyclosporine is emulsified in the small intestine, and Sandimmune® is affected by
bile flow, intestinal motility, and the presence of food, while the microemulsified
formulation is not affected by bile secretion.35,43,44 Bioavailability in dogs is
approximately 20-27% for dogs with Sandimmune®, and 35% for Atopica®, which is
largely due to the molecule size and poor solubility, even with the microemulsified
formulation.44 In humans, meal consumption within 30 minutes of taking cyclosporine
decreases the pharmacokinetic parameters area under the curve by 13% and peak
concentration by 33%.3 In dogs, administration with food decreases bioavailability by
22%, and causes higher interindividual variation in drug absorption.45 Therefore, in dogs
it is recommended to administer Atopica® at least one hour before or two hours after a
meal.4 In contrast, Atopica® for cats is recommended to be administered with food,
which results in slightly higher peak concentrations and area under the curve than when
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given fasted.30 In dogs, peak cyclosporine blood concentrations are generally reached
between 1-2 hours after oral administration of the microemulsified formulation.44
Active efflux from enterocytes back to the intestinal lumen through the action of
the efflux pump P-glycoprotein, a multidrug transporter, is suggested as a potential
contributor to the variability in absorption found with cyclosporine.46 Lower Pglycoprotein function may also increase the risk of nephrotoxicity in humans.47,48 Pglycoprotein-deficient mice have been shown to have higher brain concentrations of
cyclosporine, and to also have slower drug elimination.49 In dogs, however, although
Collies commonly possess a mutation in the gene encoding P-glycoprotein (ABCB1), no
difference has been found in cyclosporine pharmacokinetics for P-glycoprotein-deficient
versus wild-type dogs.50 In a study by Mealey, no significant bioavailability differences
were identified for cyclosporine and other P-glycoprotein substrates (quinidine,
loperamide, or nelfinavir), despite dogs given loperamide displaying excessive sedation
consistent with an affected phenotype.50 Mealey suggested that intestinal P-glycoprotein
may be saturated at doses used clinically, and thus have little influence on substrate
bioavailability. Since the tested drugs were also substrates of cytochrome P450 3A
(CYP3A) metabolizing enzymes, however, which are also found in enterocytes, the roles
of P-glycoprotein versus CYP3A could not be definitively identified. Nonetheless, the
lack of significant differences in pharmacokinetics for cyclosporine in ABCB1 deficient
dogs versus normal dogs, along with the fact that polymorphisms in CYP3A4, CYP3A5
and ABCB1 are not associated with significant alterations cyclosporine pharmacokinetics
in humans,51 makes P-glycoprotein a less likely cause of variable intestinal absorption.
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Cytochrome enzymes are located in both enterocytes and the liver, and have the
potential to influence cyclosporine bioavailability through a first pass effect, as well as by
affecting cyclosporine clearance. The role of both P-glycoprotein and intestinal CYP3A
activity in cyclosporine pharmacokinetics is controversial, but one study showed despite
a 10-fold variation in intestinal CYP3A4 activity, there was no significant association
between enzyme activity and cyclosporine pharmacokinetics in humans. In this study,
32% of peak drug concentration variability and 56% of oral clearance variability were
attributed to hepatic CYP3A4 activity, compared to 30% of peak and 17% of clearance
variability attributed to intestinal P-glycoprotein expression.46 The author is not aware of
any studies in veterinary medicine examining intestinal CYP3A activity and Atopica®
bioavailability, but it is possible factors like P-glycoprotein and CYP3A expression may
influence local drug concentrations and thus cyclosporine effectiveness for conditions
like inflammatory bowel disease, where more studies are needed to determine if there is a
correlation between blood concentrations and clinical outcome.
Distribution
Being highly lipophilic, cyclosporine is extensively distributed to body tissues
other than the central nervous system, which is protected by transporters such as Pglycoprotein.39 Cyclosporine’s volume of distribution is 3-5 L/kg, and the drug is 90%
protein bound in blood, primarily to lipoproteins, and only 8% to other blood proteins
like albumin.1,41 According to Novartis, in blood approximately 33-47% of the drug is
found in plasma, 41-58% is in erythrocytes, 5-12% is in granulocytes, and the remaining
4-9% is in lymphocytes.41 Within tissues, a study of autopsied humans on cyclosporine
for organ transplantation revealed the highest amount of cyclosporine and metabolites per
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kilogram of tissue in pancreas, followed by spleen, liver, fat, kidney, lung, bone marrow,
muscle (heart) and whole blood.52 Also in this study, fat was found to contain almost
exclusively unmetabolized cyclosporine, suggesting a possible role for obesity in
cyclosporine pharmacokinetic variability, and the need to dose cyclosporine on lean body
weight.
Cyclosporine is also recognized to concentrate in the skin, and a trial of human
psoriasis patients found skin concentrations similar to those found in blood at peak
cyclosporine levels, approximately 10 times greater than trough cyclosporine blood
concentrations.53 Steffan and others at Novartis showed that cyclosporine also
concentrates in the skin of dogs. After 14 days of administration, canine skin
concentrations were 2.5-6.4 times greater than the blood cyclosporine concentration at 4
hours, and at 24 hours blood concentrations were < 25 ng/mL, while skin concentrations
were still 206 ng/g. The authors suggested that once daily dosing is effective for atopic
dermatitis in dogs because of cyclosporine’s concentration in, and slow depletion from,
skin.54 Another study by Gray and others also showed that cyclosporine accumulates in
the skin of dogs dosed for seven days, and only a moderate correlation was noted
between skin and blood cyclosporine concentrations.55
Metabolism
Cyclosporine is extensively metabolized, and less than 1% of the drug is
eliminated unchanged in the feces,56 with a similar proportion in urine.57,58 Cyclosporine
is metabolized by CYP3A enzymes, primarily through N-demethylation and
hydroxylation.59 There are various reports of the number of metabolites, with most
sources listing greater than 25 identified.1,60,61 Metabolites are named “A” for being
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metabolites of cyclosporine A, “M” for metabolite, and then a number based on the
amino acid hydroxylation site, or the amino acid number and “N” if the metabolite is
modified by demethylation.62 There are three primary metabolites, considered first
generation metabolites produced through phase I metabolism, that are the most
biologically active.1,62 These are: AM1 (formerly M-17), 1-beta (8’) hydroxylated; AM9
(formerly M-1), 9-gamma hydroxylated; and AM4N (formerly M-21), 4-N-demethylated.
The cyclized metabolite AM1c (formerly M-18) 1-beta 1-epsilon is also commonly
measured.60,62
AM1 is considered the most biologically active metabolite, having 10-20% the
activity of the parent cyclosporine molecule.62 In a study by Venkataramanan and others,
cyclosporine metabolites were collected via choledochoureterostomy in Beagles, and
results suggested that AM9 and AM4N were the primary metabolites in dogs, with lesser
amounts of AM1 and AM1c. Cats also produce primarily AM9 and AM4N.58 Humans
primarily excrete AM1 in bile, followed by AM9, AM4N and AM1c.58 Clear differences
in metabolic pathways are present between species, with dogs recognized to have high
hepatic enzyme activity and higher concentrations of the metabolite AM4N than
humans.60
The different metabolites have different affinities for blood components, with
some found in the plasma, and others, like the parent cyclosporine, associating more with
cellular elements.1 The metabolites also have different affinities for cyclophilin, with
cyclosporine having the greatest affinity, followed by AM1 and AM9.63 The ability to
bind cyclophilin has been reported, fairly logically, as a requirement for the
immunosuppressive action of metabolites.64
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As described in the section on absorption, both the liver and intestines contain
significant amounts of CYP3A enzymes that contribute to the first pass effect and
reduced bioavailability of cyclosporine.1,65 In humans, cyclosporine is also metabolized
to AM1 in the kidney, as shown using organ slice cultures, but this is not apparent for
canine kidney slices.66 The toxicity of individual metabolites is contested, but it is
possible metabolite formation differences in the kidney could contribute to the greater
nephrotoxicity caused by cyclosporine in humans than dogs.
Since cytochrome P450 activity is so important to cyclosporine disposition in
patients, various attempts have been made to predict patient response to cyclosporine
based on CYP activity. Originally, an erythromycin breath test was developed by
Watkins. After giving intravenous 14C-N-methyl erythromycin, 14C-containing carbon
dioxide (14CO2) was measured in breath, and a negative correlation was shown between
cyclosporine blood concentration and the breath level of 14CO2.67 More recently,
extensive efforts have been made in pharmacogenetic assessments of different CYP
single nucleotide polymorphisms (SNPs). CYP3A4 is the primary cyclosporine
metabolizing enzyme in humans, with a smaller role for CYP3A5.68 The analogous CYP
in dogs for CYP3A4 is considered to be CYP3A12.69 A CYP3A5*3 SNP has been found
to influence tacrolimus pharmacokinetics, but has less convincing influence on
cyclosporine.68 The low functioning CYP3A4*22 mutation has recently been discovered,
however, and has been found to decrease clearance and increase peak cyclosporine
concentrations, and is a risk factor for worse renal function in human patients.70-72
Pharmacogenetics is a new field in veterinary medicine, but future investigations could
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evaluate the influence of cytochrome expression in canine cyclosporine
pharmacokinetics.
Elimination
Cyclosporine has a low to moderate hepatic extraction ratio,73,74 and thus hepatic
blood flow variation has less influence on clearance, while metabolizing enzyme activity
more significantly impacts cyclosporine clearance. Drug interactions are common
because of the multitude of CYP3A substrates, and drugs that impact CYP3A enzyme
activity can have a significant impact on cyclosporine pharmacokinetics (see drug
interactions). Cyclosporine is primarily eliminated through the bile, with less than 1% as
parent compound, and the majority as metabolites.56 Renal elimination of the parent
molecule and metabolites is less than 6% of the administered dose in humans.57,75 Most
sources report similar (minimal) renal excretion for dogs,32,44,76 though one early
radiolabeled study reported 10.4 ± 5.7% urinary radioactivity excretion after oral dosing,
and 17.5 ± 3.2% urinary excretion after intravenous dosing when collected for 96 hours.75
The half-life is variable, but for dogs given Atopica® cyclosporine half-life is reported as
4.5 hours.39
Mechanism of Action
After entering the cell though passive diffusion,35 cyclosporine binds to the
cytoplasmic protein cyclophilin A.77 Cyclophilins are a group of proteins with peptidylprolyl isomerase activity conserved across mammals, plants, fungi, and insects. They
help stabilize the cis-trans transition, which is important for protein folding and
multidomain protein assembly.78 Cyclophilins are considered immunophilins, a protein
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group that includes cyclophilin A, the binding target for cyclosporine, and FK506 binding
proteins (FKBPs) for tacrolimus. Cyclophilin A is found in the largest amounts in T
cells, erythrocytes, colonic epithelium, kidney and brain cells, and is widely distributed in
other body tissues at lower concentrations.63,79 Cyclosporine’s binding to cyclophilin is
highly specific, and is not displaced by co-incubation with a number of drugs including
other P-glycoprotein substrates such as rhodamine and vincristine, steroids such as
triamcinolone and dexamethasone, or the enzyme inducer rifampin.79 Indeed, in the
initial report by Handschumacher describing cyclophilin as the cytoplasmic binding
target for cyclosporine, only natural and synthetic cyclosporine analogs able to inhibit
mixed lymphocyte reactions were able to displace cyclosporine from binding
cyclophilin.77
The cyclosporine-cyclophilin complex then inhibits calcineurin, a serinethreonine phosphatase.80 Like cyclophilin, calcineurin is widely distributed in tissues
(most concentrated in the brain) and is found in mammals, plants, and fungi.81
Calcineurin has a catalytic A subunit, and a calcium-binding B subunit, and after binding
both calcium and calmodulin, the enzyme becomes active through either loss of
inhibition from the autoinhibitory domain, or changes in catalytic site affinity depending
whether calcium binds the A subunit, or B subunit, respectively.82 Though not
structurally similar, cyclosporine bound to cyclophilin A and tacrolimus bound to FKBP
both bind the B subunit, B subunit binding helix, and part of the calcineurin heterodimer
substrate-binding cleft, and impair calcineurin’s ability to bind substrates, with greater
effect for larger substrates.82 The difference in structure between tacrolimus and
cyclosporine likely accounts for their calcineurin inhibition abilities, with 10 times lower
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concentrations of tacrolimus needed to inhibit calcineurin and decrease IL-2 production
by 50%.80 In addition to its role in T cell activation, calcineurin has roles in calciumdependent activation processes in a variety of tissues including pancreatic beta cell
insulin secretion, skeletal and cardiac muscle hypertrophy, and multiple functions in the
brain associated with memory, ion channel regulation, and neuritogenesis.81
In normal T cell activation, signal transduction through the T cell receptor in
response to the cognate antigen provides signal 1. Binding of the CD28 receptor by
CD80 or CD86 on antigen presenting cells provides signal 2 (costimulation).83 This
begins an intracellular signaling cascade with the activation of phospholipase C-γ, which
hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to diacylglycerol and inositol
1,4,5 trisphosphate (IP3). Diacylglycerol and IP3 are second messengers, with
diacylglycerol activating protein kinase C, and IP3 triggering release of calcium from the
endoplasmic reticulum.84 This influx of calcium allows activation of calcineurin, whose
normal role in T cells is to dephosphorylate the transcription factor NFAT.
Phosphorylation of NFAT keeps it in the cytosol because the nuclear localization
sequence cannot be recognized by nuclear transporters.83 Once dephosphorylated, NFAT
translocates to the nucleus and increases the expression of pro-inflammatory genes like
IL-2, IL-4, IFN-γ, and TNF-α.85 Calcineurin inhibitors like cyclosporine and tacrolimus
block the dephosphorylation of NFAT, and thus reduce production of cytokines, like IL2, that normally drive the proliferation of T cells. T cells are particularly sensitive to
cyclosporine because they have naturally low expression of calcineurin.83
Cyclosporine has minimal effects on humoral immunity, and has been shown to
have no effect on IgG, IgM, or IgA secretion after intravenous dosing of 2 and 5 mg/kg
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intravenously once daily for 21 days in dogs. Both proliferative responses to T cell
mitogens and cytotoxic activity are impaired, however, reflecting cyclosporine’s primary
action against T lymphocytes.86 Cyclosporine has less effect on secondary responses
from lymphocytes that are already activated.87 Cyclosporine does have effects on other
cells that may influence its therapeutic efficacy, particularly for skin disease.
Cyclosporine has, for example, been shown to decrease histamine release from mast cells
both in vitro and in vivo in dogs.88,89 Various other effects have been reported in humans
and rodents, including reduced eosinophil numbers and granule release, as well as
decreased epidermal Langerhans cells.44
Adverse Effects
Cyclosporine’s most well recognized adverse reaction is nephrotoxicity.
Cyclosporine is well documented as potentially causing both acute and chronic renal
damage after transplantation in humans, and is especially recognized as a factor limiting
long-term survival of renal allograft recipients.8,47,90-92 Cyclosporine nephrotoxicity is
suggested to have multiple mechanisms including activation of the renin-angiotensinaldosterone system, increased endothelin-1, loss of sympathetic regulation, increased
production of transforming growth factor (TGF)-β leading to fibrosis, and direct
inhibition of calcineurin in the kidney.47 Cyclosporine is also recognized to alter the
production of thromboxanes and prostaglandins in the kidney. There is a binding site for
NFAT on the cyclooxygenase-2 (COX-2) promoter, and NFAT inhibition by
cyclosporine reduces the downstream production of vasodilators like prostaglandin E2,
and may therefore contribute to renal vasoconstriction.93 Loss of immunophilin function
because of calcineurin inhibitor binding has also been investigated as a reason for
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calcineurin inhibitor nephrotoxicity. Transgenic mice with lower cyclophilin A, the
cytoplasmic binding target for cyclosporine, have been shown to experience more severe
cyclosporine nephrotoxicity than mice with normal amounts of cyclophilin A.94 In
contrast, reduced FKBP immunophilin, the binding target for tacrolimus, has not been
shown to increase the risk for tacrolimus nephrotoxicity.95 These findings suggest that
cyclophilin A isomerase action, but not FKBP, is needed for normal kidney function.
This difference may account for the greater risk of acute tubular damage with
cyclosporine than tacrolimus.47
Acute cyclosporine nephrotoxicity generally develops within a few days of
transplantation, is reversible upon drug discontinuation, and is considered to be dosedependent and thus is reduced through therapeutic drug monitoring.47,92 Chronic
calcineurin inhibitor nephrotoxicity develops even with careful drug concentration
monitoring and drug minimization protocols, and is considered to be multifactorial.92,96
In renal transplantation, there is some controversy regarding how much of cyclosporine
nephrotoxicity is simply related to chronic graft rejection. There is no defined lesion
associated with calcineurin nephrotoxicity, but associated histopathological changes are
arteriolar hyalinosis and interstitial (also known as striped) fibrosis, although these
findings are nonspecific.91 Renal damage has also been documented in heart, lung, and
liver allograft patients, however, and demonstrates the reality of calcineurin inhibitor
nephrotoxicity. Calcineurin inhibitor minimization protocols do not eliminate the
progression of chronic nephrotoxicity, but early withdrawal protocols are being
investigated in an attempt to provide the benefit of initial graft rejection prevention using
calcineurin inhibitors, while reducing long-term exposure and chronic nephrotoxicity.96
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Fortunately, in veterinary medicine, nephrotoxicity does not seem to be a major
concern. In some of the original canine transplantation work employing very high doses
of cyclosporine (maximum 50 mg/kg/day), 5 of 34 (14%) dogs became jaundiced,
including one dog with toxoplasmosis and the remaining with hepatic necrosis. An
additional 35% died of infection, and 23% from organ rejection, but no renal changes
were reported.17 In the Atopica® approval studies, at the much lower dose of 5
mg/kg/day, vomiting (30.9%) and diarrhea (20%) were the most common adverse effects,
followed by persistent otitis externa, urinary tract infection, anorexia, lethargy, gingival
hyperplasia, and lymphadenopathy, all with less than 10% incidence.4 Bloodwork
changes that were noted included an elevated creatinine, globulin, phosphorus, protein,
cholesterol, and blood urea nitrogen, and decreased albumin and calcium.4
According to a recent review of cyclosporine adverse events, 55% of treated dogs
experienced an adverse event, but only 4% of events warranted drug discontinuation.97
Nuttall and others confirm gastrointestinal effects as the primary adverse events
associated with cyclosporine use in dogs, occurring in up to 46% of patients.97 Gingival
hyperplasia, thought to be caused by increased TGF-β production, which in turn induces
fibroblast proliferation, occurred in 1% of patients in the studies evaluated. Other less
common adverse events include verrucous dermatitis or papillomatosis, hirsutism, and
predisposition to infection. These authors found no risk of renal damage and minimal
risk of neurotoxicity, and suggested a possible risk for malignancy associated more with
the level of immunosuppression than cyclosporine itself.97 Cyclosporine is also
recognized as a contributor to insulin resistance.98,99
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Drug Interactions
As discussed under metabolism, cyclosporine is a substrate of both hepatic and
intestinal CYP3A enzymes and P-glycoprotein, making it highly susceptible to drug
interactions. Other drugs metabolized by CYP3A4 can compete for metabolism with
cyclosporine, and drugs that affect the activity of these enzymes can have significant
effects on cyclosporine blood concentrations. Many drugs are recognized to affect
cyclosporine metabolism, but the one that has been used specifically for that purpose is
ketoconazole. The azole antifungals are known inhibitors of CYP3A enzymes, and coadministration of cyclosporine and ketoconazole allows oral cyclosporine dose reductions
of up to 75% at the higher cyclosporine doses needed to maintain trough concentrations
sufficient to prevent rejection after renal transplantation in dogs,100 and up to 70-90% at
the lower doses needed for treatment of anal furunculosis.101,102 A similar effect is noted
for fluconazole, although maximal cyclosporine dose reductions of only approximately
50% are achieved in both healthy dogs and renal transplant patients.103,104
A listing of drugs with the potential to increase or decrease cyclosporine blood
concentrations is found Table 2.2. In addition to the azoles, other important drugs with
the potential to increase cyclosporine blood concentrations include the calcium channel
blockers, verapamil and diltiazem, and macrolide antibiotics.76,105 Drugs that act as
CYP3A inducers and have the potential to reduce cyclosporine blood concentrations
through increased metabolism include phenobarbital, rifampin, phenylbutazone,
phenytoin, and carbamazepine.35 Different glucocorticoids also have the potential to
either increase or decrease cyclosporine blood concentrations. Prednisone and
methylprednisone are CYP3A inhibitors, while dexamethasone is a CYP3A inducer.105
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Natural biological products have also been found to affect CYP3A, and thus
cyclosporine blood concentrations. Grapefruit contains compounds called
furanocoumarins that inhibit intestinal CYP3A enzyme activity.106 This effect was
shown in a study that documented increased peak blood cyclosporine concentrations and
area under the curve (AUC) for human subjects that drank grapefruit juice before and
after oral cyclosporine dosing. These subjects experienced increased cyclosporine
bioavailability after oral dosing, but no change in drug clearance. No effect on
intravenous cyclosporine pharmacokinetics was noted, suggesting the effect to be
mediated during drug absorption, likely by alteration in intestinal CYP3A activity.107 In
dogs, cyclosporine administered with 100 mL of liquid grapefruit juice or 10 g of freezedried grapefruit juice approximately doubled the maximum drug concentration (Cmax) in
3 dogs, and AUC increased by 25% and 27% for liquid and freeze-dried grapefruit,
respectively.108 In another study of 6 dogs, powdered grapefruit significantly increased
AUC by 54%, but utilized a large dose of grapefruit powder (10 g) that was not
considered to be cost-effective.109 In contrast, St. John’s Wort, an herb used for
depression in people, has been shown to induce CYP3A enzymes and P-glycoprotein in
humans and rats.110 Consistent with these findings, St. John’s Wort decreased
cyclosporine AUC and Cmax after 7 days of co-administration in dogs, and increased
cyclosporine clearance.111
The role of P-glycoprotein in drug interactions is less clear, but many of the drugs
that affect CYP3A function also have a parallel effect on the function of P-glycoprotein.
Ketoconazole and the other azole antifungals inhibit both CYP3A and P-glycoprotein,
while St. John’s Wort and rifampin induce both CYP3A and P-glycoprotein. Other drugs
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recognized as inhibitors of P-glycoprotein include verapamil, diltiazem, erythromycin,
quinidine, fluoxetine, and spinosad.112 Other drugs that are substrates, and thus could
compete with cyclosporine for efflux pumps such as P-glycoprotein, include digoxin,
colchicine, and fexofenadine.113 Despite the number of shared inhibitors, studies have
found poor correlations between the concentration of drug that inhibits P-glycoprotein
and CYP3A4 function by 50% (IC50) for the multiple inhibitors tested, possibly because
of variability in in vitro measurements of P-glycoprotein activity.114-116
Table 2.1

Drugs potentially affecting cyclosporine blood concentrations

Increase cyclosporine
Acetazolamide
Allopurinol
Amlodipine
Azithromycin
Azole antifungals
Bromocriptine
Calcium channel blockers
Carvedilol
Chloramphenicol
Cimetidine
Ciprofloxacin/enrofloxacin
Cisapride
Clarithromycin
Clopidogrel
Colchicine
Danazol
Digoxin

Erythromycin
Estrogens
Fluvoxamine
Glipizide/glyburide
Grapefruit juice/powder
Imipenem
Losartan/valsartan
Medroxyprogesterone
Methylprednisolone
Metoclopramide
Metronidazole
Midazolam
Omeprazole
Prednisone/prednisolone
Sertraline
Tinidazole
Vitamin E

Decrease cyclosporine
Azathioprine
Carbamazepine
Clindamycin
Cyclophosphamide
Dexamethasone
Famotidine
Griseofulvin
Octreotide
Phenobarbital
Phenytoin
Rifampin
St. John's Wort
Sulfadiazine/sulfamethoxazole
Sulfasalazine
Terbinafine
Trimethoprim
Warfarin

Table showing drug interactions affecting cyclosporine blood concentrations. This list
includes drugs affecting both CYP3A and P-glycoprotein, and others with unconfirmed
mechanisms. Items listed in italics have been shown to be of limited relevance for
dogs.44,97,105,117
Despite a multitude of possible drug interactions, several studies have shown the
more minor drug interactions (that is, not azoles) to have a limited effect on cyclosporine
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pharmacokinetics. The clinical significance of increased cyclosporine blood
concentrations caused by drug interactions is also less in dogs than in people because
elevated cyclosporine concentrations do not carry the risk of nephrotoxicity found in
human medicine.44 No interaction was shown between methylprednisolone (1
mg/kg/day) and high dose cyclosporine (20 mg/kg/day) when the drugs were coadministered to dogs for 2 weeks in a drug safety study, though full pharmacokinetic
details were not described.29,44 Metoclopramide is reported to increase cyclosporine
AUC in humans, but a similar finding was not reported in a study of 8 dogs.109 Similarly,
cimetidine is a potent hepatic microsomal enzyme inhibitor, but only delayed the
absorption of cyclosporine in dogs, and did not affect total drug exposure.118 Individual
dog variability in blood concentrations at similar drug doses is consistently high,
however, even with the microemulsified formulation of cyclosporine.44,97,118 Therefore,
blood cyclosporine concentration monitoring should be considered with coadministration of potentially interacting drugs if drug interaction is suspected based on
therapeutic failure or adverse events, or when treating more life-threatening diseases
where obtaining adequate cyclosporine blood concentrations has greater clinical
significance.
In addition to being subject to a number of drug interactions, cyclosporine can
also alter the blood concentrations of other medications. Cyclosporine is a competitive
inhibitor of P-glycoprotein.119 Cyclosporine also inhibits the same CYP enzymes it is
metabolized by,120,121 and has been shown to reduce the activity of the organic anion
transporter (OAT) 1B1 (also known as OATP2) located on the hepatocyte basolateral
membrane.122,123 Inhibition of P-glycoprotein, CYP enzymes and OAT1B1 is suspected
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to, in combination, contribute to the increased blood concentrations of statins found in
patients also treated with cyclosporine.123,124 Similar concentration increases for the
antidiabetic drug repaglinide were noted in humans given cyclosporine, and this was
attributed to cyclosporine-mediated inhibition of OAT1B1 and CYP3A4.125 These
effects are drug specific, however, as cyclosporine co-administered with diltiazem,
another CYP3A and P-glycoprotein substrate, does not affect diltiazem pharmacokinetics
in people, although blood cyclosporine AUC and peak concentrations are increased.126
Drug-drug interactions are even more difficult to predict in veterinary medicine,
where less is known about cytochrome metabolic pathways and variations in Pglycoprotein or OAT affinity. One drug-drug interaction investigation using canine
hepatic microsomes showed some CYP2B11 inhibition by cyclosporine, and a greater
effect on CYP3A12 and CYP3A26,127 but all the substrates of these cytochromes in dogs
have not been determined. Caution should be taken when administering cyclosporine
with other drugs metabolized and excreted through similar pathways, especially those
with narrow therapeutic indexes such as doxorubicin, vincristine, and digoxin, which all
require P-glycoprotein for excretion.112,113
Monitoring
Since cyclosporine has a narrow therapeutic index, monitoring of blood drug
concentrations has been a priority since the drug was introduced to human medicine.
Interestingly, since chemical assays or immunoassays were not initially available, the
first assays of cyclosporine’s effects were bioassays measuring the drug’s effects on
lymphocyte responses to mitogens.2 In the first report of human renal cadaveric
transplants (1978), Calne and others reported taking weekly serum samples and
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incubating transplant patient serum with healthy lymphocytes to determine the serum’s
ability to inhibit proliferation induced by phytohemagglutinin (PHA).19 Analytical
techniques were soon developed, and a tremendous amount of literature is published
regarding different methods and sample timings in an effort to correlate blood
concentrations with clinical outcome. Throughout the drug’s use, there have also been
studies evaluating pharmacodynamic assays as a way to investigate immune responses to
cyclosporine to possibly explain some of the variability in clinical outcomes that has been
appreciated despite attainment of similar blood concentrations. This section will first
review assays used for blood concentration determination and strategies for cyclosporine
monitoring, and will then proceed to a discussion of pharmacodynamic monitoring efforts
in humans and animals.
Pharmacokinetics
Analytical Methods
High performance liquid chromatography (HPLC) was the first technique
published for cyclosporine quantitation,128 and is still considered the gold standard.
HPLC is able to individually identify cyclosporine and its metabolites, and the
metabolites were originally named in part by their elution times on the
chromatograph.62,129 As the metabolite chemical structures have been elucidated,
metabolite names have since changed to reflect the position of chemical modification and
the action performed (hydroxylation or N-demethylation).129 According to Wang and
others, “HPLC is considered to be the most difficult to perform, the most accurate, the
least precise, and the most time consuming” assay.130
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Shortly after the development of an HPLC assay, a radioimmunoassay (RIA) was
created with polyclonal antibodies harvested from rabbits inoculated with cyclosporin C.
Significant cross-reactivity with the parent cyclosporin A and its metabolites was
recognized.131 Other polyclonal immunoassays were developed, and though easier to
perform, the results were consistently higher than those found with HPLC, and
sometimes led to clinically significant differences. This was noted by Burckart and
others in a study of pediatric liver transplant patients, where poor liver function in the
first week after transplantation led to lower metabolite excretion and much higher RIA
results than those found with HPLC.132
A more specific monoclonal antibody was then developed by Quesniaux and
others at Sandoz,133 and was incorporated into both radioimmunoassays and a
fluorescence polarization immunoassay (FPIA).130,134,135 These more specific RIAs and
the FPIA showed improved correlation with HPLC, and were simpler to perform. The
TDx FPIA developed by Abbott performed particularly well, and decreased sample
processing time for 20 samples to approximately 30 minutes (versus 2-4 hours for the
monoclonal RIA), and lowered detection limits, with cross-reactivity with metabolites of
15.3% for AM9, 8.2% for AM1, 3.7% for AM4N, and less than 3% for the other
metabolites.130,136,137 The TDx FPIA had values approximately 24% higher than those
evaluated with HPLC in one study.136 Newer assays have since been developed including
a chemiluminescent polarization immunoassay (ARCHITECT, Abbott) that has replaced
the TDx assay, and a chemiluminescence immunoassay (ADVIA Centaur®, Siemens), as
well as a magnetic particle immunoassay with photometric detection (ACMIA).138-140
These assays report even better correlation with HPLC, and limited metabolite cross33

reactivity.138,139 One study showed ACMIA results to be only 1.7% higher than those
determined with liquid chromatography-tandem mass spectrometry (LC-MS/MS).139
Interference is still a potential issue for immunoassays, however, as was noted for
the ACMIA assay, when a patient’s blood drug concentrations were still in the
therapeutic range after stopping cyclosporine treatment.140 The issue was suspected to be
interference from anti-animal antibodies that may have developed while the patient was
being treated with thymoglobulin, which contains rabbit immunoglobulin. Immunoassay
interference, though uncommon, is most often the result of circulating anti-animal
antibodies and lower affinity heterophile antibodies, and can be blocked by incubating
the serum with a heterophilic blocking reagent.140
Presently, in veterinary medicine, both HPLC and immunoassays are reported.
HPLC seems more common for post-transplant monitoring and some research
projects,25,26,55,141,142 while the large reference laboratory that is currently measuring
cyclosporine blood concentrations uses a magnetic particle immunoassay.143
Importantly, as described above, different assays will have different levels of crossreactivity with cyclosporine metabolites. The impact of cross-reactivity is less significant
for newer methods, but with the old TDx assay, Cmax and AUC were 1.5-1.7 times
higher than results found with HPLC for dogs dosed with oral cyclosporine, and the assay
was reported to cross react with AM1 and AM9 in dogs.45 It is recommended to refer to
the reference ranges provided by the individual laboratories when interpreting
cyclosporine blood concentrations, but variability in blood concentrations achieved
through different methods has long been recognized as a significant contributor to the
difficulty in establishing a therapeutic range for cyclosporine.135
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Sample/Matrix
Initially, there was controversy regarding which sample was best for measuring
cyclosporine concentrations. Whole blood and plasma were used, but the amount of
cyclosporine found in plasma was quickly recognized to vary with temperature, with
lower plasma concentrations at lower temperatures.144 A 30-minute equilibration at 37°C
was recommended prior to separating the plasma, but even this did not solve the issue of
poor correlation between blood and plasma drug concentrations.145 Plasma
concentrations also varied inversely with hematocrit,146 which is logical given that 4158% of blood cyclosporine is in erythrocytes, while only 33-47% of the drug is found in
plasma.36,41 Proponents of using plasma cyclosporine concentrations proposed that
results were more representative of the free drug concentration, and potentially more
likely to correlate with toxicity and efficacy.87,147 Whole blood concentrations correlated
better with kidney concentrations than plasma,148 however, and ultimately to better
standardize measurements and reduce variation across monitoring centers, whole blood
measurement became recommended.129,149
More recently, researchers have quantified intracellular cyclosporine in
lymphocytes and peripheral blood mononuclear cells (PBMC).150-153 Crettol and others
showed that lymphocyte cyclosporine concentrations were only moderately correlated
with whole blood concentrations. P-glycoprotein SNPs have a stronger effect on
lymphocyte cyclosporine concentration than whole blood drug concentration, suggesting
P-glycoprotein activity as potentially an important factor in individual immune responses
to cyclosporine.154 Supporting the importance of lymphocyte cyclosporine
concentrations, decreased intracellular cyclosporine was identified by Falck and others 3
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days before traditional measures indicated kidney rejection, while whole blood levels
were unchanged. In addition, patients that experienced organ rejection within the first
three months also had lower intracellular cyclosporine AUC0-12 than patients not
experiencing rejection. Measurement of intracellular cyclosporine, however, shows high
inter- and intra-patient variability.155
Trough
The most traditional method of cyclosporine monitoring is through trough drug
concentration evaluation before the next dose is administered. One of the individuals
most integral to optimizing cyclosporine monitoring strategies is Barry Kahan. Initially,
Kahan proposed the trough concentration as the preferred time for measurement because
it was the most reproducible value and less likely to be affected by variability in drug
absorption and distribution,87 which was a particular issue for the Sandimmune®
formulation. In a study of 118 patients, Kahan found trough concentrations to be better
correlated with clinical events than peak concentrations.156 He proposed that peak
concentrations were not well correlated with toxicity, but acknowledged it was yet to be
determined if achieving a certain peak was needed to prevent rejection.87,156 Two other
early studies showed reasonable to good correlations between cyclosporine plasma
concentrations and both rejection and toxicity,147,157 but most other efforts struggled to
find a clearly defined therapeutic range for cyclosporine.135 Indeed, despite significant
investigation into different pharmacokinetic parameters, frustration with poor correlations
with both nephrotoxicity and rejection led The Ohio State University to publish an article
titled “Cyclosporine levels are not helpful.”158,159
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As described below, Kahan and others went on to investigate other monitoring
strategies, including AUC and peak concentrations. These measures, and the
development of the microemulsified cyclosporine formulation, led to improved
pharmacokinetic-clinical correlations. Debate persists today, however, regarding the best
strategy for therapeutic drug monitoring, and trough drug concentrations are still
frequently used.140,160,161
Trough concentrations are also the only reasonably well-described target in
veterinary medicine. Whole blood trough concentrations between 300-500 ng/mL27,141
and 400-700 ng/mL26 are recommended by different authors for renal transplantation in
dogs, while target feline post-transplant concentrations are lower at 250-400 ng/mL162
and 300-500 ng/mL.25 Therapeutic drug monitoring is also proposed when treating anal
furunculosis in dogs. Initial recommendations were trough whole blood concentrations
between 400-600 ng/mL as measured by monoclonal RIA,163 but subsequent efforts to
reduce cost through combined treatment with ketoconazole achieved success by targeting
trough whole blood concentrations of at least 200 ng/mL as measured by HPLC.101 Less
information is available for other inflammatory diseases, but Dawn Boothe’s clinical
pharmacology laboratory at Auburn University recommends trough concentrations of
400-600 ng/mL for immune-mediated diseases and 250 ng/mL for chronic inflammatory
disorders like inflammatory bowel disease39 Trough blood concentrations, however, have
not been shown to correlate with clinical efficacy in cases of atopic dermatitis or anal
furunculosis.45,164
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Area Under the Curve
Subsequent studies in human medicine showed that multiple blood samplings and
calculation of the AUC or average steady state concentration (AUC/dosing interval in
hours) was more highly correlated with clinical outcomes, and the dose administered,
than trough sampling.165-168 Unfortunately, AUC measurements require repeated
sampling, which is more labor intensive, expensive, and uncomfortable to the patient.
Significant effort (38 papers as of 2001)169 was therefore directed at establishing limited
sampling strategies that still correlated with AUC. Measurements at 2, 6, and 24
hours,170 2, 6, and 14 hours,171 3.5, 8, and 10 hours,172 and others were proposed, and
equations derived to approximate full measurement AUC values.
The introduction of the Neoral® formulation in 1995 improved cyclosporine
absorption and reduced pharmacokinetic variation. Shorter sampling strategies such as
the AUC0-4 were investigated and found to correlate well with both rejection and
toxicity.173-175 Indeed, in a prospective trial, Mahalati and others were able to propose a
therapeutic window (AUC0-4 4400 to 5500 μg/h per L) where only 1/33 (3%) patients that
achieved the target blood concentration experienced rejection, while 10/22 (45%) patients
lower than the window experienced acute rejection. In addition, no patients in the
therapeutic range experienced cyclosporine nephrotoxicity, while four patients above the
range experienced nephrotoxicity. Trough concentrations and weight-adjusted
cyclosporine dose both correlated poorly with AUC0-4.174
AUC is still considered the most reliable method for cyclosporine monitoring in
human medicine,161,176 but is infrequently used because of cost and inconvenience. No

38

veterinary studies have attempted correlating cyclosporine AUCs to clinical response to
the author’s knowledge, likely for similar reasons.
Peak
Once troughs were recognized to provide an inaccurate predictor of response to
cyclosporine, single samples at times other than trough began to be investigated in
parallel with the above described AUC limited sampling methods. Initial investigations
for Sandimmune® suggested sampling times of 5 or 6 hours after dosing as being better at
reflecting AUC and clinical outcomes.172,177 With Neoral®, in contrast, peak blood drug
concentrations reliably occur between 1-2 hours after oral dosing.41 In his review on the
progress of therapeutic drug monitoring of cyclosporine, Kahan reminds the reader of the
mathematical concept that the maximum concentration will most closely correlate with
the AUC. This was more difficult to establish for Sandimmune® where the time to
maximum blood concentration (Tmax) can be from 2 to 6 hours (and likely why single
peak sampling times as late as 5-6 hours post-dosing were proposed as best in earlier
studies), but application of this principle suggested 2 hours as potentially the most
optimal time for Neoral® monitoring.90
In support of this, peak (2 hours post oral administration) blood concentrations
were found to better correlated with AUC than trough levels in multiple studies.174,176,178180

Many studies have focused on the therapeutic benefit of C2 (peak) over C0 (trough)

monitoring long term, with various studies showing equal to better performance for C2
monitoring. Citterio and others reported a clinical benefit to cyclosporine monitoring
after heart transplantation for 69.3% of patients monitored with C2, versus 43.3%
monitored with C0, though mortality was not different between the two periods.181 A
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study of liver transplant patients noted lower rates of acute rejection in a C2 monitored
group, lower incidence of rejection in patients that reached target C2 levels by 3 days,
and a lower incidence of moderate to severe changes in biopsy-proven acute rejections
than with C0 monitored patients.182 In renal transplants, C2 monitoring resulted in a low
incidence of biopsy-proven acute rejection in the MO2ART study,183 and a long-term
management study showed C2 monitoring allowed dose reductions in 49% of the
assessed patients, and this improved serum creatinine and lowered blood pressure in 54%
of that patient subset.184
One limitation of peak sample evaluation is that some of the assays for
cyclosporine blood concentration are not able to measure the high blood concentrations
found at peak times, and thus require sample dilution. This is the case for the Abbott
ARCHITECT assay, which requires samples to be diluted at concentrations greater than
1500 ng/mL.185 The ACMIA that is also commonly used requires samples to be diluted
at concentrations higher than 2000 ng/mL.186 As an example of typical peak levels, the
MO2ART study targeted cyclosporine peak concentrations of 1600-2000 ng/mL in the
first month after transplant.183 Dilution protocols were evaluated in 2004, and were
shown to increase variability in drug monitoring results.187 Dilution protocols are better
described for more modern systems, but still have the potential to influence results.
In veterinary medicine, peak concentrations are just beginning to be evaluated.
Little enough information is available regarding target trough concentrations for different
disease states, and even less information is available to make peak recommendations. Dr.
Boothe at Auburn recommends a target peak concentration of 800-1400 ng/mL or a
trough concentration of 400-600 ng/mL for diseases where high immunosuppression is
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required. She goes on to state that, based on the short half-life of cyclosporine in dogs
(approximately 5 hours), peaks of 1600-2400 ng/mL may be required to maintain desired
trough concentrations, or even as high as 2600-3000 ng/mL if a trough of 750 ng/mL is
desired after transplantation.39 More work in veterinary medicine is needed to determine
if peak or trough concentrations correlate with outcome in clinic patients treated with
cyclosporine for non-dermatologic diseases.
Despite the strong evidence in humans that C2 blood concentrations are more
representative of AUC and cyclosporine exposure than trough, and the growing evidence
that C2 may be better correlated to outcome, as of 2011, Peter and others wrote “Most
transplantation centers, including ours, use the whole-blood trough concentration to
adjust cyclosporine dosing.”140 Another C0 supporter, Filler, commented that the better
correlation of C2 with AUC did not imply good agreement, and cited substantial variation
noted from a Bland-Altman analysis. Filler considered the precise sampling required for
peak concentrations to be an issue in pediatric transplantation, and suggested trough
monitoring to be more “robust.”188 A critical evaluation of the two randomized
controlled trials evaluating C2 monitoring in liver transplant patients (including the study
described above) present at the time of writing in 2006 noted several study limitations
that limited the strength of the conclusions drawn, including low power of the studies,
high study withdrawal, and lack of information on dose adjustments.189 Figures from a
survey of monitoring practices in 2004 reported 97.3% of laboratories were evaluating
EDTA-anticoagulated whole blood, and that 66% of centers were using C0 monitoring
alone, 6% C2 alone, and 24% C2 in combination with C0 or AUC.187 Unfortunately,
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more recent data cannot be found, possibly because of a recent trend in human transplant
medicine to use tacrolimus instead of cyclosporine, especially in the United States.
Pharmacodynamics
Pharmacodynamic assays evaluate the influence of cyclosporine on its therapeutic
target, the T cell. Achievement of pharmacokinetic targets may be less clinically
important than attaining adequate suppression of T cell function, which can be measured
with pharmacodynamic assays. Importantly, achieving a certain blood cyclosporine
concentration does not guarantee sufficient immune suppression, and conversely a given
concentration may cause excessive suppression in an individual, increasing the risk for
infection and malignancy. The reasons for this variability in individual response are less
understood, but may include factors such as variability in P-glycoprotein and calcineurin
activity within lymphocytes among individuals. Pharmacodynamic assays are also useful
because some are able to identify the cumulative effect of co-administered
immunosuppressive medications, and have been used to evaluate drug mechanisms and
interactions.190-193
As mentioned above, it is interesting that the initial method for blood
cyclosporine determination was a pharmacodynamic assay evaluating lymphocyte
proliferation.2,19 There are many types of pharmacodynamic assays available to evaluate
cyclosporine response, with most measuring some aspect of lymphocyte activation and
cytokine response, since impaired IL-2 production (necessary for T cell activation and
proliferation) is the primary mechanism of action of cyclosporine. Lymphocyte
proliferation, surface antigen expression, cytokine production, and calcineurin activity
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have all been evaluated in human clinical patients. These investigations and the
preliminary work available in veterinary medicine are described below.
Proliferation Assays
The first bioassays for cyclosporine blood concentration determination measured
proliferative responses of lectin-stimulated lymphocytes treated with cyclosporine via
[3H]-thymidine incorporation.2 Greater inhibition of proliferation corresponded to a
higher cyclosporine blood concentration. Subsequent work confirmed that cyclosporine
inhibited proliferation induced not only by the lectin PHA, but also by OKT3 (an antiCD3 monoclonal antibody) and mixed lymphocyte culture.194 Spontaneous blastogenesis
(proliferation) assays were also used in the 1980s to identify “strong immune
responders”, that were shown to be at greater risk of transplant rejection than weak
responders, when treated with azathioprine and prednisone.195 Cyclosporine decreased
immune responses of strong responders to the level of weak responders, and decreased
rejection episodes relative to azathioprine.196 Hibbins and others used a different
approach and evaluated lymphocyte proliferation in patient lymphocytes activated ex vivo
with PHA and incubated with varying concentrations of methylprednisolone and
cyclosporine. A steeper gradient of inhibition indicated a greater response to the drug,
and renal transplant patients with a steeper gradient were shown to be more responsive to
methylprednisolone and cyclosporine after transplantation. The authors suggested this
approach as a way to predict patient response, though gradients were not significantly
different among patients that rejected their transplants and those that did not.197
Proliferation assays are a commonly used in vitro technique to evaluate the effects
of various immunosuppressive drugs, with many studies determining the IC50, which in
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this context reflects the concentration of drug required to inhibit cell proliferation by
50%.198,199 These in vitro proliferation assays have also been used to explore drug
interactions, and evaluate the effects of combination immunosuppressive therapy at
various drug concentrations.190,193,200,201 Similar to the approach of Hibbins, IC50
determinations after concanavalin A-stimulated blastogenesis were used to identify
resistance to cyclosporine and glucocorticoids in ulcerative colitis patients, and patients
with low glucocorticoid sensitivity in vitro were found to require higher prednisone doses
for control of clinical signs.202
More recently, proliferation assays have been included in pharmacodynamic
panels investigating patient immune responses after transplantation.203-206 Tritiated
thymidine is still used occasionally to measure proliferation, but flow cytometry has
become popular for its simplicity, with the most common assay using proliferating cellnuclear antigen (PCNA) and propidium iodide.204,207 Studies have shown reduced
lymphocyte proliferation in transplant patients relative to healthy controls,206 and
reductions in lymphocyte proliferation at peak compared to trough cyclosporine
levels.203,204,208,209 Barten and others used lymphocyte proliferation, surface antigens, and
cytokines to monitor immune suppression in patients changed from cyclosporine to
tacrolimus and sirolimus,204 and found proliferation to be among the pharmacodynamic
parameters with the strongest correlation to cyclosporine blood concentrations.204,209
Since proliferation is known to be impacted by cyclosporine and other drugs given after
transplantation, such as steroids, mycophenolate, sirolimus, and leflunomide,
proliferation assays provide a more global assessment of immune function during multidrug treatment.
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Markers of Activation
Surface Antigens
Various antigens are expressed on the surface of T cells, and change once T cells
receive an activation signal through the T cell receptor and costimulation through CD28
by an antigen presenting cell. Common markers of T cell activation include: CD25, the
alpha subunit of the IL-2 receptor; CD95, the FAS receptor that signals apoptosis; CD134
(OX40), necessary for T cell survival after costimulation; CD154, the activating ligand
for CD40 found on antigen presenting cells; CD11a, important for adhesion and
diapedesis; CD69, important for cell activation, proliferation, and differentiation; and
CD71, the transferrin receptor.210 Various combinations of surface antigens are
commonly included in pharmacodynamic assays, and two studies by Barten showed
lymphocyte proliferation and surface antigens were in general better correlated with
cyclosporine blood concentrations than cytokines in human heart transplant recipients,
and also showed lower surface antigen expression at peak versus trough blood
concentrations.204,208 A study by Stalder and others also showed lower surface antigen
expression (CD25, CD95, CD71, CD11a, and CD154) after oral cyclosporine therapy.206
Another study showed higher levels of CD4 positive, IL-2 receptor positive peripheral
blood lymphocytes in heart transplant patients prior to a rejection episode, while IL-1 and
IL-2 were unchanged.211 As with proliferation assays, surface antigens can be influenced
by co-administered medications. A study validating human pharmacodynamic assays
found concentration-dependent inhibition of CD25 and CD71 by cyclosporine,
tacrolimus, sirolimus, mycophenolic acid, and methylprednisone when incubated in vitro,
although sirolimus only had a small effect on CD25.207
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Cytokines
As far back as 1985, a study by Yoshimura and Kahan identified decreased IL-2
production from T cells of renal transplant patients treated with cyclosporine, and
correlated higher IL-2 production (reflecting less effective cyclosporine-mediated
suppression) with episodes of rejection.212 NFAT-regulated cytokines, especially IL-2,
IFN-γ, TNF-α, and granulocyte macrophage colony stimulating factor (GM-CSF) have
since become popular pharmacodynamic measures of cyclosporine’s effects. Although
glucocorticoids can also decrease transcription of cytokines, one immunologic biomarker
validation study found that in vitro inhibition of IL-2 was significant only for the
calcineurin inhibitors cyclosporine and tacrolimus, and not for methylprednisolone,
mycophenolic acid, or sirolimus.207 In this study, samples were activated with phorbol
12-myristate 13-acetate (PMA) and ionomycin for 4 hours, and cytokines were measured
with flow cytometry.207 Freed and others showed methylprednisolone sodium succinate
did inhibit IL-2 production after concanavalin A (ConA) stimulation for 24-32 hours,213
however, so the influence of concurrent medications is likely affected by the method and
duration of stimulation. As another example, IL-2 messenger ribonucleic acid (mRNA)
expression was suppressed in a concentration-dependent manner by cyclosporine, but
was not affected by incubation with prednisolone or mycophenolic acid after a 2-hour
incubation with the drug and PMA plus ionomycin.214 Though not as specific as
calcineurin inhibition, cytokine monitoring most likely still offers a more targeted
reflection of the effects of cyclosporine on the patient than surface antigens or
lymphocyte proliferation.
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Monitoring of IL-2, IFN-γ, and other cytokines has been frequently performed in
vitro to evaluate immunosuppressive drug effects,198,207,215,216 and ex vivo after
transplantation.204,217-221 Brunet and others showed peak but not trough IL-2 levels as
measured by ELISA were significantly lower in transplant patients treated with
cyclosporine than levels in healthy control patients. They also included a cyclosporine
plus mycophenolate group where both peak and trough IL-2 were lower than healthy
controls, and the peak cyclosporine plus mycophenolate also had significantly lower IL-2
than cyclosporine alone. These patients were also all treated with steroids.221 In another
study by Brunet of patients on cyclosporine, mycophenolate, and steroids, IL-2 and IFN-γ
expression 7 days after transplantation were significantly lower than healthy controls predose and 2 hours after dosing. At 6 months after transplantation, IFN-γ pre-dose was no
longer significantly different, while the other cytokine parameters remained significantly
decreased.205 Barten and others used flow cytometry to show significantly lower
expression of IL-2, IFN-γ, and TNF-α at peak relative to trough cyclosporine levels,
while IL-4 was not significantly different, in heart transplant patients.204 In a similar
study of cytokines by Barten and others, however, although all trended to decrease, only
IL-2, IL-4, and IL-10 were significantly lower for the peak versus trough sample, and
IFN-γ, TNF-α, and IL-8 were not significantly different.208 Hodge and others evaluated
intracellular cytokines after lung transplantation and found reduced T cell IL-2 and TNFα, but increased IL-4 relative to controls. They also specifically evaluated the CD4 and
CD8 positive T cell subsets and found reduced IFN-γ expression by CD4 but not CD8
positive cells, and increased TGF-β expression by CD8 positive cells.222
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As described here, two approaches for cytokine monitoring are either to compare
to a healthy control, or to compare the pre-dose and 2-hour sample. The general trend is
for lower NFAT-regulated cytokine expression at peak cyclosporine blood concentrations
relative to trough, and for lower cytokine levels after transplantation relative to healthy
controls, though some cytokines like IL-4 are variable. A notable cytokine exception is
TGF-β, which increases with cyclosporine therapy, and is higher at peak than trough
cyclosporine levels.203 Cytokine levels do not always reflect clinical events, however.
As mentioned earlier, Yoshimura and Kahan associated higher IL-2 with rejection, but
other studies failed to show a correlation between IL-2 and IFN-γ and rejection,223 and
even found lower IL-2 mRNA expression prior to rejection in some patients.224 Others
have shown increased IFN-γ relative to pre-transplant levels in patients with acute kidney
rejection.225
Notable approaches to cytokine measurement include Härtel and others, who used
a more physiologic activating stimulus (anti-CD3 and anti-CD28 monoclonal antibodies)
and evaluated IL-2, IL-4 and TNF-α mRNA for different durations of incubation (0, 4, 8
and 24 hours). This group found a delayed increase in cytokine mRNA expression
during costimulation in patients treated with cyclosporine, and proposed the “area of
cytokine mRNA expression over time” as a potentially more sensitive way to assess
immunosuppressive drugs.220 The work of Giese, Zeier, Meuer and others at the
University of Heidelberg also suggests a promising method for cytokine monitoring.
This group calculates the mean residual gene expression for IL-2, IFN-γ, and GM-CSF
by dividing the peak adjusted number of gene transcripts by the trough gene transcripts,
and averaging the values for the three cytokines evaluated.219 This method is suggested
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to be more specific for cyclosporine because patients take other immunosuppressive
medications separate from this two hour window, and their assay, which uses PMA and
ionomycin stimulated cytokine expression, is reportedly insensitive to the effects of
steroids and azathioprine in vitro.218 With this approach, a mean reduction in cytokine
expression of 85% was found at two hours, and patient gene expression had recovered to
trough levels by six hours after dosing.226 A lower residual gene expression (and thus
greater immunosuppression) has been associated with a higher risk of both infection and
neoplasia,227,228 and with a greater risk of non-melanoma skin cancer.229 These authors
have successfully tapered cyclosporine therapy in stable renal transplant patients based
on residual gene expression, which improved patient blood pressure and prevented the
worsening of renal allograft function that was identified in the control (non-tapered)
group.219 Based on this study and others, the authors suggested a target of 20-30%
residual NFAT-regulated gene expression in long-term stable renal transplant patients,
which is supported by an increased incidence of skin cancer in patients with gene
expression below 15%, and an acute rejection episode documented in a patient with
residual gene expression above 40%.161,219,229
Calcineurin Inhibition
Measuring calcineurin inhibition is the most specific measure of the direct effects
of cyclosporine and tacrolimus, but is more technically challenging. In T cells,
calcineurin activity is regulated by the presence of intracellular calcium, which is
increased after T cell receptor binding. In vitro assays are performed with an excess of
all reagents, and thus do not fully reflect actual intracellular calcineurin activity.
Protocols involve measuring calcineurin’s ability to dephosphorylate a 19 amino acid
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peptide that is part of the bovine cardiac cyclic AMP-dependent protein kinase regulatory
subunit (RII). Other serine-threonine phosphatases (PP1, PP2A, and PP2C) can also
dephosphorylate RII, so okadaic acid is included to inactivate PP1 and PP2A, and some
protocols include either cyclosporine or ethyleneglycoltetraacetic acid (EGTA), the latter
to chelate calcium, with both blocking calcineurin action and thus revealing PP2C
effects.210 HPLC with ultraviolet detection can be used to identify the dephosphorylated
peptide, a scintillation counter can be used to measure 32P if the peptide is radiolabeled,
and a colorimetric assay with malachite green has also been used.161,210
Calcineurin inhibition has been shown to parallel cyclosporine blood
concentrations, and occurs rapidly after cyclosporine dosing.230 Halloran and others
showed calcineurin levels to be significantly suppressed by 1 hour after cyclosporine
administration and to remain suppressed through 4 hours after dosing, while 6, 8, and 12
hours were not significantly different than pre-dose calcineurin levels.230 KoefoedNielsen and others also examined the temporal profile of calcineurin inhibition after oral
cyclosporine, and found a significant decrease by 1 hour, maximal suppression at 3 hours
but, at the end of sampling at 6 hours, calcineurin levels did not return fully to baseline
and were still significantly different than pre-dose.231 In both of these studies, an inverse
correlation between cyclosporine concentration and calcineurin was identified. In
another study of renal transplant patients, however, calcineurin inhibition was variable,
and no correlation was identified between calcineurin inhibition and cyclosporine blood
concentration at 0 or 2 hours, or between calcineurin inhibition and cyclosporine AUC0232

12.
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Calcineurin inhibition has not been well correlated with patient toxicity, but has
been associated with transplant rejection in some transplant patients. Brunet and others
showed lower trough calcineurin inhibition significantly correlated with biopsy-proven
acute rejection in renal transplant patients on cyclosporine and mycophenolate.205
Fukudo and others identified increased calcineurin activity in patients with acute
rejection treated with both cyclosporine and tacrolimus relative to patients that did not
experience rejection.233 Higher calcineurin activity was identified in patients with graft
versus host disease after allogeneic stem-cell transplantation in one study,234 while in
contrast an older study actually found lower calcineurin activity in cyclosporine-treated
patients experiencing graft versus host disease.235
Other Assays
Other pharmacodynamic measures have also been used to monitor cyclosporine
treatment. The ImmuKnow® Immune Cell Function Assay developed by Cylex with the
patent now held by Viracor-IBT LaboratoriesTM was cleared by the FDA in 2002 as a
nonspecific measure of immunosuppression in transplant patients. The test measures
adenosine triphosphate (ATP) production from CD4-positive T cells after a 15-18 hour
incubation with PHA using luciferin and a luminometer.236 Lower ATP production
reflects greater immunosuppression, and reportedly measures drug-associated
immunosuppression regardless of which immunosuppressive drugs are used. Many
studies of this assay have been performed, and while some do correlate lower
ImmunoKnow® ATP levels with infection and higher ATP levels with rejection,237-239
other studies have not found clear associations with clinical outcomes.240,241
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In a recent study by Barten’s group, dendritic cell numbers were evaluated in
heart transplant patients. The study revealed that higher numbers of plasmacytoid
dendritic cells were associated with a lower risk of rejection, and that patients treated
with tacrolimus had higher plasmacytoid dendritic cell numbers than cyclosporine-treated
patients. Further study was recommended to define dendritic cell numbers that would
predict rejection.242
Sample Handling
Similar to the discussions surrounding the best sample for pharmacokinetic
analysis of cyclosporine use, different methods for pharmacodynamic sample evaluation
have also been proposed. Older studies used PBMC or cell lines to have a purer cell
population for evaluation. More recently, whole blood assays have been investigated to
more closely mimic cell populations present in vivo, to avoid washing the drug out of the
cytoplasm, and to maintain drug distribution among blood components. Whole blood
assays showed similar responses as PBMC for proliferation assays in response to in vitro
drug incubation,199 while cytokine responses, as measured by immunoassay, for PBMC
versus diluted whole blood stimulated with PHA depended on the cytokine. Interleukin-6
and GM-CSF responses were similar, TNF-α and IFN-γ were higher in whole blood than
PBMC, and IL-1 and IL-2 were higher in PBMC than whole blood.243 In a study
assessing the IC50 for calcineurin inhibition from in vitro cyclosporine, calcineurin
inhibition was both significantly greater and more variable in PBMC versus whole
blood.230 Another study showed greater calcineurin inhibition by cyclosporine in culture
medium than whole blood, and this was attributed to cyclosporine partitioning to nontarget areas in whole blood.244 Overall, whole blood assays are preferred where possible,
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are generally technically less challenging and time-consuming, and seem to have less
variability than assays performed with PBMC.
The activating protocol chosen also has the potential to influence test results.
Most pharmacodynamic assays involve stimulating lymphocytes to induce proliferation
and expression of activation-related surface antigens and cytokines. The most common T
cell mitogens include ConA, PHA, mixed lymphocyte reactions, anti-CD3/anti-CD28
monoclonal antibodies, and PMA plus the calcium ionophore ionomycin. Fortunately, a
study using microarrays found very similar gene expression patterns among T cells
activated with anti-CD3 beads, PHA, costimulatory beads (anti-CD3/anti-CD28), and
PMA plus ionomycin.245 Most studies use PMA and ionomycin for cytokine evaluation,
and ConA for cell proliferation and surface antigen evaluation. A recent study attempting
to validate techniques for biomarker evaluation in human whole blood suggested
evaluating surface antigens after 72 hours incubation with 7.5 μg/mL ConA, and
cytokines (IL-2 and TNF-α) after 4 hours with 15 ng/mL PMA and 0.75 μg/mL
ionomycin.207
Pharmacodynamics in Veterinary Medicine
Very few studies have been performed investigating cyclosporine immune
responses in veterinary medicine. A 1986 study showed PBMC from dogs treated with
intravenous cyclosporine that were washed free of plasma actually had enhanced
blastogenesis in the presence of ConA and PHA, while PBMC from untreated dogs
incubated with 10% plasma from treated dogs showed suppression of proliferation that
was greatest with plasma from 3 hours after cyclosporine dosing, and returned to baseline
when incubated with plasma drawn at 72 hours. PBMC activated with PHA were more
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sensitive to the effects of the cyclosporine-treated plasma than those activated with
ConA.246 Results of this study suggested that cyclosporine’s effects on lymphocytes
were reversible, and also confirmed that PBMC isolation affects results in canine
samples. Recently, a study by Nafe and others evaluated IC50 concentrations for canine
PBMC incubated with different immunosuppressive agents. They reported an IC50 to
inhibit proliferation for cyclosporine of 15.8 +/- 2.3 ng/mL,247 which is significantly
lower than whole blood IC50 values reported for calcineurin inhibition ex vivo (253
ng/mL)230 and IL-2 in vitro (173-340 ng/mL)214 in humans, and may again be affected by
the lack of non-target cyclosporine partitioning in PBMC in culture media. Strangely,
this is also dramatically lower than cyclosporine IC50 values for proliferation for both
human whole blood (384 ng/mL) and PBMC (345 ng/mL) after PHA stimulation, though
Nafe and others measured proliferation using flow cytometry, whereas the human study
used tritiated thymidine incorporation.199 A low proliferation IC50 (55 ng/mL) was also
documented for feline diluted whole blood when incubated with cyclosporine and ConA,
possibly suggesting species variability.248
Cyclosporine’s effects have also been evaluated on cytokine expression in vitro
using qRT-PCR. Kobayashi and others showed concentration-dependent suppression of
IL-2, IL-4, and IFN-γ in PBMC incubated with ConA and varying concentrations of
cyclosporine for 5 hours, but an increase in TNF-α mRNA expression at 810 ng/mL of
cyclosporine.249 In a study of ConA-stimulated PBMC in cats (samples incubated for 10
hours), in vitro cyclosporine also showed a concentration-dependent inhibition of IL-2,
IL-4, IFN-γ, and TNF-α. Cytokines were significantly decreased at cyclosporine
concentrations of 150 ng/mL, and reached maximal suppression at 450 ng/mL. 1000
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ng/mL of cyclosporine was also associated with a lower frequency of IL-2 secreting cells
than untreated samples (measured with enzyme-linked immunospot assay).250
Studies of cyclosporine’s immunological effects in veterinary disease are even
more scarce. A study of mRNA expression in tissue from canine anal furunculosis
lesions showed significantly lower lesional IL-2 mRNA expression after cyclosporine
treatment, and a trend towards lower IFN-γ.251 In Allenspach’s study of cyclosporine for
the treatment of inflammatory bowel disease in dogs, reduced T lymphocyte numbers
(but not total lymphocytes) were noted on intestinal biopsy samples of dogs performed
after 10 weeks of oral cyclosporine therapy.252 Topical ophthalmic cyclosporine’s
systemic effects have been evaluated in two studies. Gilger and others identified reduced
PHA-stimulated PBMC proliferation after 1 months’ treatment with 2% cyclosporine,
that became significantly reduced relative to healthy patients by 3 months.253 In contrast
to this finding, Williams identified no effect of cyclosporine 0.2% ointment
(Optimmune®) or 2% cyclosporine in corn oil on PHA or ConA driven PBMC
proliferation after 1, 3, or 6 months of treatment. The highest blood concentration
identified in this study was 15 ng/mL as measured using mass spectroscopy.254 The
author is not aware of any studies attempting to correlate pharmacodynamic measures to
cyclosporine response in dogs or cats.
Monitoring Conclusions
In their attempt to validate immunologic biomarkers, Böhler and others
acknowledged that the primary limitation of pharmacodynamic assays is the lack of a
target for immune suppression that is well correlated to patient outcome, and commented
that this may not even be possible given that individual patients may require different
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degrees of immunosuppression for clinical efficacy.207 Similarly, Barten and others
acknowledged although pharmacodynamic assays clearly document a response to
immunosuppressive agents, targets for inhibition are not known, and it is also uncertain
whether proliferative responses need to be compared to pretreatment levels, or over
time.204
Thus, although pharmacodynamic assays offer the chance to assess immune
responses, there are similar limitations to pharmacokinetic assays, with both assays
presenting the greatest opportunity for intervention at the extremes of test responses. A
very low blood cyclosporine concentration or very low inhibition of pharmacodynamic
parameters increases the potential for treatment failure, while extremely high blood
concentrations or complete immune suppression increase the potential for drug side
effects, secondary infections, and cancer. Unfortunately, with appropriate blood
concentrations and moderate suppression of immune function, it is still possible
individual patients may respond unsatisfactorily. Pharmacokinetics and
pharmacodynamics are thus likely both necessary to optimize immunosuppressive
therapy, and provide complementary information. Prospective pharmacodynamic trials
to develop and confirm target biomarker levels are also desperately needed to prove the
benefits of immunologic monitoring in transplant medicine. In veterinary medicine,
which has poorly defined blood cyclosporine targets and only preliminary investigations
into pharmacodynamics, much research is needed to develop assays that can be used to
monitor responses in patients treated with immunosuppressive medications, including
cyclosporine.
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Cyclosporine in Veterinary Clinical Use
The microemulsified formulation of cyclosporine, Atopica®, is approved for the
treatment of allergic skin diseases in both dogs and cats at a dose of 5 mg/kg daily in
dogs, and 7 mg/kg daily in cats. This includes atopic dermatitis in dogs, and eosinophilic
plaques, miliary dermatitis, and self-induced alopecia in cats.29,30 Many studies have
been performed evaluating cyclosporine for the treatment of atopy in dogs,255-258 and
have confirmed similar clinical responses to glucocorticoids.259,260 Similar studies have
confirmed cyclosporine’s efficacy for inflammatory skin conditions in cats.261,262
Cyclosporine concentrates in the skin, and this is suggested as a reason for the poor
correlation between blood drug concentrations and clinical outcome found by Steffan and
others in treating atopic dogs.45 The other approved formulation of cyclosporine is the
ophthalmic preparation, Optimmune®, labeled for the treatment of keratoconjunctivitis
sicca in dogs.
Cyclosporine has also been used for the extralabel treatment of other
dermatologic conditions in dogs including sebaceous adenitis, pemphigus foliaceus, and
anal furunculosis. Cyclosporine was effective in 12 dogs treated for sebaceous
adenitis,263 but did not fully resolve signs of pemphigus foliaceus in any of the 5 dogs
reported.264 Conversely, cyclosporine was found to be glucocorticoid sparing and
effective in the treatment of 6 cats with pemphigus.265 Cyclosporine is well documented
as an effective treatment for anal furunculosis,163,164,266-268 and is often combined with
ketoconazole to impair CYP3A metabolism and allow higher blood cyclosporine
concentrations to be reached with a lower oral cyclosporine dose.101,269 This is especially
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important since anal furunculosis frequently affects large breed dogs such as German
shepherds and Labrador retrievers.
In addition to its dermatologic uses, cyclosporine is used for other immunemediated diseases in both dogs and cats. Allenspach and others showed improvement in
12 of 14 dogs with steroid-refractory inflammatory bowel disease treated with
cyclosporine at a dose of 5 mg/kg daily. Though these authors measured blood
concentrations, they felt that the limited number of samples precluded their ability to
assess correlations between drug concentrations and clinical response.252 Cyclosporine
has also been reported for the treatment of immune-mediated polyarthritis in dogs. A
retrospective study reported poor success of cyclosporine at 5 mg/kg daily in 3 dogs,270
but a more recent prospective trial documented successful treatment in 7 of 10 dogs
started at a dose of 5 mg/kg cyclosporine every 12 hours, with doses increased if
necessary to reach a minimum trough blood cyclosporine concentration of 250 ng/mL if
clinical signs were not improved within the first 7-14 days. In this study, some dogs
experienced clinical improvement with trough blood cyclosporine concentrations as low
as 70 ng/mL.271 Cyclosporine was also used in the successful treatment of chronic
progressive polyarthritis in a female cat.272
Less information is available regarding cyclosporine’s use for hematologic
disorders, but it is used at higher doses (up to 10 mg/kg every 12-24 hours) for the
treatment of immune-mediated hemolytic anemia (IMHA) and thrombocytopenia in dogs.
In a study of 276 dogs with IMHA, 10.9% patients received cyclosporine as the primary
immunosuppressive drug at a dose of 3-7 (median 5) mg/kg once daily, while 10.5% of
dogs received it as a second-line drug at a dose of 2-7 (median 3.3) mg/kg every 12
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hours.273 A retrospective cross-sectional analysis of 88 IMHA dogs reported
cyclosporine as an adjunctive treatment in 27% dogs, with a typical dose of 9.4 mg/kg
once daily or 6.15 mg/kg twice daily. In this study, there was no significant effect on
survival to discharge for cyclosporine coadministration.274 A small, 38 patient,
prospective, double-masked randomized controlled trial showed no benefit of
cyclosporine (3-5 mg/kg every 12 hours) plus prednisone (2-4 mg/kg every 24 hours)
over prednisone alone on survival, though four of the prednisone only group relapsed,
versus no dogs in the cyclosporine plus prednisone group.275 Limited evidence is
available for the treatment of immune-mediated thrombocytopenia, but one abstract
reports successful treatment in 3 of 4 dogs refractory to prednisone at a cyclosporine dose
of 12-17 mg/kg/day increased to achieve a trough of 400-600 ng/mL, though one dog
died of systemic aspergillosis.276 Cyclosporine has also been reported in combination
with prednisolone for the treatment of pure red cell aplasia in cats,277 and was successful
for the treatment of 1 cat with immune-mediated thrombocytopenia.278
Extralabel cyclosporine is also used for other inflammatory conditions.
Cyclosporine at a dose of 2.5 mg/kg twice daily was successful in reducing stomatitis
scores of cats that had persistent stomatitis after full or partial mouth extractions in a
randomized, double-masked, placebo-controlled study. Interestingly, 72.3% of cats with
a cyclosporine trough greater than 300 ng/mL had clinical improvement, versus 28.2% in
cats with blood cyclosporine concentrations less than 300 ng/mL.279 A randomized,
placebo-controlled trial of cyclosporine for the treatment of glomerulonephritis at a dose
of 10 mg/kg every 24 hours adjusted to maintain a trough blood concentration of 250-400
ng/mL revealed median survival times of 16 months for placebo-treated dogs versus 11
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months with cyclosporine, thus cyclosporine was not recommended for treatment of
canine glomerulonephritis.280
In neurology, cyclosporine reportedly improved clinical signs of myasthenia
gravis in 2 dogs that were refractory to treatment with pyridostigmine and
glucocorticoids.281 Cyclosporine has also been successfully used for the treatment of
meningoencephalomyelitis of unknown etiology (MUE) in dogs. Two studies used a
cyclosporine dose of 10 mg/kg once daily282 or 6 mg/kg twice daily,283 respectively,
while a third reported a target drug trough concentration of 200-400 ng/mL when
cyclosporine was used with prednisone and/or ketoconazole.284 Though cyclosporine
does not normally cross the blood-brain barrier, Adamo and others suggested that the
inflammation associated with MUE allows therapeutic cyclosporine concentrations to
reach the central nervous system (CNS), or alternatively that cyclosporine’s effect on
peripheral lymphoid organs recognized to initiate autoimmune disease is sufficient to
reduce CNS inflammation without cyclosporine penetrating the blood-brain barrier.284
Finally, cyclosporine is used for renal transplantation in both dogs and cats,
although much more commonly in cats since renal transplantation in dogs has poor
success rates.25-28 Whole blood trough cyclosporine concentrations between 300-700
ng/mL26,27,141 are recommended by different authors for renal transplantation in dogs,
while feline post-transplant concentrations are lower at 250-500 ng/mL.25,162 Most
transplant centers in veterinary medicine measure cyclosporine blood concentrations
using HPLC.
There are many current and potential applications for cyclosporine within
veterinary medicine. The wide range of dosing strategies offers an opportunity to
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correlate biomarker levels, blood drug concentrations, and clinical response. The
following chapters describe initial efforts to develop a panel of biomarkers to measure
cyclosporine immune responses in the dog.
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Abstract
Cyclosporine is a powerful immunosuppressive drug that is being used with
increasing frequency to treat a wide range of immune-mediated diseases in the dog. To
date, ideal dosing protocols that will achieve immunosuppression with cyclosporine in
dogs remain unclear, and standard methods that can measure effectiveness of
immunosuppression have not been established. The aim of our study was to evaluate the
effects of in vitro cyclosporine exposure on a panel of molecules expressed by activated
T cells to ascertain their potential as biomarkers of immunosuppression in dogs. Blood
was drawn from six healthy dogs, and peripheral blood mononuclear cells (PBMC) were
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isolated and activated. Half of the cells were incubated with 200 ng/mL cyclosporine
prior to activation, and the other half were not exposed to cyclosporine. Samples were
analyzed using flow cytometry, and the expression of intracellular cytokines IL-2, IL-4,
and IFN-γ was evaluated after 6, 12, and 24 h of drug exposure. Each cytokine exhibited
a time-dependent suppression profile, and all but two samples activated in the presence of
cyclosporine showed lower cytokine expression than untreated controls. We also
evaluated the expression of the surface T cell activation molecules CD25 and CD95 by
flow cytometry after 36 h of drug exposure. Expression of these surface molecules
decreased significantly when activated in the presence of cyclosporine. Our results
suggest that suppressed expression of the markers related to T cell activation could
potentially be utilized as an indicator of the efficacy of cyclosporine therapy in dogs.
Introduction
Cyclosporine (CsA) is an important immunosuppressive drug with uses in both
human and veterinary medicine. Veterinary applications include treatment of atopic
dermatitis, anal furunculosis, inflammatory bowel disease, and a variety of other
inflammatory and immune-mediated diseases.1-3 Derived from the fungus Tolypocladium
inflatum, CsA is a hydrophobic cyclic endecapeptide. It specifically targets T cell
function, potently inhibiting cell-mediated immunity with relatively less effect on
humoral immunity.4 Inside T cells, CsA forms a complex with cyclophilin, which then
binds to calcineurin preventing its activation. Calcineurin, a calcium-dependent
serine/threonine phosphatase, is therefore unable to activate nuclear factor of activated T
cells (NFAT) which regulates the production of several important cytokines including IL2, IL-4, TNF-α and IFN-γ.5,6 Reduced production of IL-2, important for IL-2 dependent
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growth and differentiation of T cells, is thought to be the main cause of the
immunosuppressive effects of CsA.7
Orally administered CsA is preferred for long term therapy and at home use in
canine patients, but the bioavailability of available oral formulations is unpredictable.
This necessitates the use of therapeutic drug monitoring to ensure that treatment is
adequate, particularly when CsA is administered for potentially life-threatening
conditions. Currently, pharmacokinetic assays measuring drug concentrations in the
blood over time are the primary means to monitor CsA therapy in dogs. The
pharmacokinetics of CsA in both people and dogs are well described,1,8-10 however,
individual humans and dogs may not respond identically to the same blood level of CsA.
Additionally, target CsA blood levels were originally established in dogs undergoing
renal transplantation. These levels were extrapolated from human transplant literature and
then empirically adjusted to achieve drug levels sufficient to prevent organ rejection in
dogs while minimizing adverse effects.11 These target blood levels are those needed to
prevent organ rejection, and may not be relevant for treatment of all naturally occurring
canine inflammatory and immune-mediated diseases. Indeed, in pharmacokinetic studies
of dogs with atopic dermatitis, no significant correlation was found between CsA blood
level and response to therapy.8,10,12 Pharmacodynamic assays that study the relevant
biological effects of a drug offer another option for CsA monitoring that may be more
applicable to the veterinary patient.
There are numerous studies in the human literature pertaining to
pharmacodynamic monitoring of CsA therapy,13-18 but few studies exist in the veterinary
field. The effect of CsA on canine mRNA expression of various cytokines has been
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investigated,19-21 and lymphocyte proliferation has been analyzed after topical CsA
therapy for keratoconjunctivitis sicca22 and systemic CsA treatment.23 However, in vitro
flow cytometric analysis of the effects of CsA on the production of cytokines and surface
molecules by circulating T lymphocytes has not been performed in the dog.
In our study, we used flow cytometry to measure the production of a panel of
biomarkers, IL-2, IL-4, IFN-γ, CD25 and CD95, that have been found to be downregulated in humans treated with CsA.14 As mentioned previously, IL-2, IL-4, and IFN-γ
are cytokines whose production is regulated by NFAT.5,6 CD25 (IL-2Rα) and CD95
(FasR) are T cell surface molecules with roles in activation and T cell development.24,25
The goals of our study were to examine the utility of these biomarkers in evaluating the
in vitro effects of CsA on canine lymphocytes and to determine the potential of these
markers as pharmacodynamic measures of immunosuppression in dogs.
Materials and Methods
Animals
Six healthy adult Walker hounds, with no previous history of disease, were used
as blood donors. Complete blood counts with differentials were performed periodically
on each dog to ensure that cell counts were within the normal range. The dogs were
housed in a university setting under standard conditions, and Institutional Animal Care
and Use Committee (IACUC) approved protocols were followed.
Reagents
Complete media (CM) was prepared using RPMI 1640 supplemented with 10%
heat-inactivated FBS, 1× GlutaMAXTM, 1mM sodium pyruvate, 55μM 287

mercaptoethanol, 75μg/mL gentamicin, 2mM HEPES, and 1μL/mL MEM amino acids
solution without L-glutamine. For PBMC isolation, Histopaque®-1077 was purchased
from Sigma–Aldrich (St. Louis, MO). Stock solutions of ConA (Sigma–Aldrich) were
made with Ca2+-Mg2+-free PBS (PBS) at 1mg/mL. PMA and ionomycin were also
purchased from Sigma–Aldrich, and stock solutions of 10mg/mL PMA and 1mM
ionomycin were made in 100% ethanol. Brefeldin A and the BD Cytofix/Cytoperm Plus
Kit were purchased from Becton Dickinson (San Jose, CA).
Antibodies used for intracellular staining were: FITC-conjugated monoclonal
anti-dog CD3 (MCA1774F, AbD Serotec, Raleigh, NC), R-phycoerythrin (RPE)conjugated monoclonal anti-bovine IL-4 (MCA1820PE, AbD Serotec), RPE-conjugated
monoclonal anti-bovine IFN-γ (MCA1783PE, AbD Serotec), and biotinylated anti-canine
IL-2 (BAF1815, R&D Systems, Minneapolis, MN). RPE-conjugated streptavidin
(#60669, Anaspec, San Jose, CA) was used as a secondary label for IL-2. For surface
molecule staining, RPE-conjugated anti-dog CD3 (MCA1774PE, AbD Serotec) was used
with purified rabbit polyclonal antibodies for anti-CD25 (IL-2R, sc-664, Santa Cruz
Biotechnology, Santa Cruz, CA) and anti-CD95 (GTX13550, Genetex, Irvine, CA).
FITC-conjugated goat anti-rabbit IgG antibody (GTX77059, Genetex) was used as a
secondary antibody for the surface molecules. Isotype controls were purchased from
Santa Cruz Biotechnology.
CsA was obtained from Bedford Laboratories (Bedford, OH). Injectable CsA at
50mg/mL was diluted, using 0.9% sodium chloride solution, to a concentration of
25μg/mL and was added to sample CM to reach a final concentration of 200ng/mL. This
value was chosen because CsA concentrations higher than this resulted in negligible
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additional suppression of mRNA expression during quantitative RT-PCR in dogs,19 and
pilot studies in our laboratory showed it to be an effective drug concentration. Target
trough cyclosporine blood levels in dogs vary widely depending on method and sample
tested, and range from 100 to 600ng/mL.26-28 A concentration of 200ng/mL for PBMC in
media and serum was therefore postulated to be comparable to therapeutic levels in vivo.
Blood collection and PBMC isolation
Blood was drawn from the jugular vein of each dog and collected in heparinized
tubes. PBMC were immediately isolated by density gradient centrifugation using
Histopaque®-1077 similarly to the previously described method.29 After isolation, cells
were reconstituted in CM to a total volume equaling that of the original whole blood
sample. This established a cell concentration approximately equivalent to that initially
present in the healthy canine donors. All donors had white blood cell counts and
differentials that were within the normal canine ranges.
T cell cytokine assay
200ng/mL CsA was added to half of the cells prior to activation, and the other
cells were in CM only during this period. After 90min, PMA and ionomycin were added
to the activated sample wells at a final concentration of 12.5ng/mL PMA and 0.8μM
ionomycin, and all cells were incubated for 6, 12, or 24h at 37°C in a 5% CO2 incubator.
With 2h remaining in that incubation, brefeldin A was added at a final concentration of
1μg/mL to stop cytokine secretion from the T cells. After incubation, cells were collected
from the wells (300μL per sample) and washed with PBS. Each sample was then
incubated with FITC-conjugated anti-CD3 antibody for 30min at room temperature in the
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dark to label the T cell population. Next, cells were fixed and permeabilized using the BD
Cytofix/Cytoperm Plus Kit with slight modifications from the manufacturer’s
instructions. Briefly, cells were fixed in the fixation/permeabilizing solution for 20min,
centrifuged (400 × g for 7min), the supernatants aspirated, and incubated with 1x BD
perm/wash for 10min, centrifuged again (400 × g for 7min), and the supernatants
aspirated. Cells were then incubated with either RPE-conjugated anti-bovine IL-4, RPEconjugated anti-bovine IFN-γ, or biotinylated anti-canine IL-2 for 30min at room
temperature in the dark. Next, samples were washed with 1x BD perm/wash. The IL-2
samples had an additional 20min incubation with streptavidin at room temperature in the
dark. These samples were washed again, and all cells were resuspended in PBS with
0.2% BSA.
T cell surface molecule assay
Half of the separated PBMC were untreated, and half were incubated with
200ng/mL CsA for 90min. Half of both groups were then activated with 0.5μg/mL ConA,
and all cells were incubated for 36h at 37°C in a 5% CO2 incubator. After incubation,
cells were collected from the wells (300μL per sample) and washed with PBS. Each
sample was incubated with RPE-conjugated anti-CD3 antibody, and either purified antiCD25 antibody or purified antiCD95 antibody for 30min at room temperature in the dark.
After washing with PBS, all samples were incubated with FITC-conjugated secondary
antibody for a further 30min at room temperature in the dark. Cells were again washed
and resuspended in PBS with 0.2% BSA.

90

Flow cytometric analysis
Forward scatter (FSC) and side scatter (SSC) were used to identify and gate the
lymphocyte population, and a second gate was placed around CD3-positive cells to
identify T cells and exclude B cells. Samples were assayed using a FACSCalibur Flow
Cytometer (Becton Dickinson) and analyzed with CellQuest Pro software (Becton
Dickinson). 10,000 events were collected in all experimental groups. Cell staining was
evaluated by measuring mean fluorescence intensity (MFI) with single histogram
statistics. Unactivated samples and isotype controls were used as negative controls in our
study.
Statistical analysis
Differences in MFI and percent increase of MFI on activation between control
and CsA-treated samples were analyzed for each biomarker at each time point using the
Wilcoxon signed-rank test. Statistical analyses were performed using the UNIVARIATE
procedure in SAS for Windows® version 9.2 (SAS Institute Inc., Cary, NC). P values ≤
0.05 were considered significant. Percent increase of MFI on activation was calculated
using Formula (3.1).
% 𝐼𝑛𝑐𝑟𝑒𝑎𝑠𝑒 =

𝐴𝑐𝑡𝑖𝑣𝑎𝑡𝑒𝑑 𝑀𝐹𝐼−𝑈𝑛𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑒𝑑 𝑀𝐹𝐼
𝑈𝑛𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑒𝑑 𝑀𝐹𝐼

𝑥 100

(3.1)

Results
Intracellular cytokines
We analyzed the production of intracellular cytokines in activated cells incubated
either alone or with 200ng/mL CsA for incubation periods of 6, 12, and 24h. Fig. 3.1
shows the decrease in expression of cytokines in activated CsA-treated cells relative to
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activated untreated cells by evaluating both the percent increase in fluorescence upon
activation and the MFI following activation. The increase on activation is calculated by
comparing a sample’s unactivated fluorescence (unactivated MFI) to the fluorescence of
a second aliquot of the same sample incubated with activating stimuli (activated MFI).
This “percent increase on activation” value measures T cell function by assessing the
cells’ capacity for increasing cytokine production in response to activation. Analyzing
MFI in both the activated CsA-treated and untreated cells demonstrates the direct effect
of CsA treatment on fluorescence intensity.
For IL-2, the percent increase in fluorescence intensity on activation was reduced
in T cells exposed to CsA at 6, 12, and 24h, but this suppression was only statistically
significant at 12h. The IL-2 overall MFI increased over time, but the results became more
variable. A significant difference between the activated CsA-treated and untreated groups
was found at 6 and 12h, but this difference was no longer significant at 24h (Fig. 3.1A’).
IL-4 displayed a lower overall fluorescence, but differences were consistent so MFI and
percent increase data were both significantly reduced in T cells exposed to CsA at 6 and
12h. At 24h, although fluorescence was greater, results were again less consistent and
significance was lost (Fig. 3.1B and B’). IFN-γ samples showed a marked and consistent
effect of CsA at 6, 12, and 24h, with statistically significant reductions at all time points
for both percent increase on activation and MFI in CsA-treated cells compared to
untreated cells (Fig. 3.1C and C’). Both IL-2 and IL-4 displayed greater untreated
fluorescence at 24h than 6h, and IL-4 also demonstrated an enhanced ability to increase
on activation over time. This is in contrast to IFN-γ, which had consistent MFI and
activation levels across the testing interval.
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Figure 3.1

Cyclosporine effects on activated T cell intracellular cytokines

Increase on activation and MFI of IL-2 (A, A’), IL-4 (B, B’), and IFN-γ (C, C’), for CsAtreated activated T cells relative to untreated controls. Canine PBMC were isolated, and
half of the cells were incubated in the presence of CsA, and the other half were in CM
only. Cytokine production was evaluated by flow cytometry after 6, 12, and 24h of
activation with PMA and ionomycin. Data are analyzed by calculating the percent
increase on activation and by comparing the activated sample MFI values.
* Indicates a statistically significant difference due to the effects of CsA (P≤ 0.05).
Surface molecules
Surface molecule expression was evaluated for CsA-treated and untreated cells at
36h using 0.5μg/mL ConA as an activator. These data were analyzed using percent
increase on activation (Fig. 3.2A) and MFI (Fig. 3.2B). Similarly to IL-4, CD25 and
CD95 both had very low fluorescence. The differences in MFI and percent increase on
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activation were greater for CD95 than CD25, although both markers consistently and
significantly decreased with CsA treatment (Fig. 2A and B). Previous experiments in our
laboratory indicated 36 h to be optimal for surface molecule assays (data not shown), so
no further time points were assayed.

Figure 3.2

Cyclosporine effects on activated T cell surface molecules

Percent increase in expression on activation (A) and MFI (B) for T cell surface molecules
CD25 and CD95 after 36h of incubation. Canine PBMC were isolated and either
incubated with CsA or in CM only, and half of both groups were activated with ConA.
Surface molecule expression was evaluated for unactivated and activated samples using
flow cytometry. Data are analyzed by calculating the percent increase on activation and
by comparing the activated sample MFI values.
* Indicates a statistically significant difference due to the effects of CsA (P≤ 0.05).
Discussion
Optimal oral dosing protocols for CsA for dogs are not well established, despite
its use as a major immunosuppressive drug in veterinary medicine. The majority of
94

investigations of the immunosuppressive effects of CsA are studied in dogs with
inflammatory dermatologic or gastrointestinal disorders in which efficacy was primarily
evaluated empirically by the practitioner and the owner through the assessment of clinical
response.1,2,28,30,31 Additionally, while efficacy against several common inflammatory
diseases has been established,1,2,10 there is little information regarding the relationship
between CsA blood concentrations and the degree of immunosuppression in dogs.
Flow cytometry is a frequently used technique to study CsA effects in human
research, but has been of limited use in veterinary medicine, possibly due to the limited
availability of antibodies. Using flow cytometry, Gilger et al. described suppressed
lymphocyte proliferation after 1 to 3 months of topical 2% CsA administration in
keratoconjunctivitis sicca patients.22 In another study, CsA’s ability to suppress green
fluorescent protein (GFP)-specific immune responses against GFP-transduced
hematopoietic stem cells was evaluated.32 The use of flow cytometry to monitor systemic
CsA therapy in dogs is a novel approach, and is the goal of our research group.
In vitro, activated canine T cells showed consistent suppression of IL-2, IL-4, and
IFN-γ production when incubated in the presence of CsA. Each cytokine had an
individual suppression profile that varied over time from 6 to 24h, which, except for the
24h IL-2 time point, was consistent for the six dogs sampled. In previous work in our
laboratory (data not shown), IL-2 results were more variable at longer incubations than at
those less than 24h, and this held true in this experiment. Overall, the most consistent
data for cytokine protein expression were found with a 12h incubation, at which time all
three markers showed a significant difference in percent activation and MFI between
untreated and CsA-treated groups.
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Other pharmacodynamic assays in dogs examining cytokine mRNA expression in
cells treated with CsA have found similar results. In one study, the mRNA expression of
IL-2, IL-4, and IFN-γ was found to be inhibited in PBMC treated with CsA, but TNF-α
was found to increase.19 The suppression we identified with IL-2, IL-4, and IFN-γ
corroborates those mRNA results, and is similar to what has been found in humans.
Kobayashi’s TNF-α finding is contrary to work with human cells, however, in which
TNF-α was found to have decreased expression in the presence of in vitro CsA.33 Anticanine TNF-α antibodies for flow cytometry were unavailable at the time of publication,
so this cytokine could not be studied in our project. Another group studied IL-2 and IFNγ mRNA expression in anal furunculosis lesions in dogs, and also found decreased
cytokine levels after CsA therapy.20 Since mRNA expression does not always correlate
with the production of biologically active proteins, confirmation of changes in T cell
cytokine production by flow cytometry is valuable. A study in cynomolgus monkeys
found comparable results when analyzing CsA effects using flow cytometry and
quantitative RT-PCR.34 A similar study in dogs is warranted to identify whether
quantitative RT-PCR or flow cytometry is more sensitive at detecting changes in T cell
cytokine production, and could direct future pharmacodynamic work.
The expression of surface molecules CD25 and CD95 also decreased in the
presence of CsA. The response of T cell surface molecules to immunosuppressive
therapy has been evaluated in human whole blood, where expression of both CD25 and
CD95 was found to decrease in the presence of CsA.13,14 These samples were incubated
for three days, but in our laboratory, 36h provided a more optimal incubation period. Our
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assay provides the first determination of the response of canine T cell surface molecules
to CsA in vitro, and confirms a comparable effect to that found in humans.
This study is the first to use flow cytometry to measure T cell cytokine and
surface molecule expression as pharmacodynamic measures of CsA immunosuppression
in dogs. With our identification of a panel of biomarkers that both increase upon
activation and are suppressed by CsA, further investigation is warranted to determine if
expression of the markers is suppressed in dogs treated with oral CsA using an ex vivo
assay. In order for the assays to be clinically valuable, suppression will need to be dosedependent. Further work could also involve correlating our pharmacodynamic assays
with traditional pharmacokinetic blood CsA levels. It is not known whether dogs will
respond identically and predictably to a certain blood drug level, or if suppression of
biomarkers of immunosuppression from a baseline established for each dog will be
required in order to optimize immunosuppressive therapy. Böhler et al. conducted a
rigorous analysis of several immunosuppressive markers in humans, and examined both
intra-assay and inter-individual variation. An analogous investigation into the
reproducibility of results in dogs would help identify a pharmacodynamic strategy for
veterinary CsA monitoring.35
In conclusion, there is a clear need for pharmacodynamic studies that establish
target CsA levels that are relevant to immune-mediated diseases commonly encountered
in canine practice, but to date such studies have been very limited in number and scope.
Assays that reflect actual T cell function hold promise as objective measures of the level
of immunosuppression present in the body, and could help identify a better way to utilize
CsA in clinical patients. This report describes one such assay that used flow cytometry to
97

evaluate the ability of T cells to express activation molecules and produce cytokines. We
demonstrated substantial suppression of five canine immunological markers when
exposed to in vitro CsA. These results suggest that CsA has a similar mechanism in dogs
to that found in humans, and that flow cytometric assays may be a valuable tool for
measuring CsA effects in dogs.
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Abstract
Cyclosporine and glucocorticoids are powerful immunosuppressive agents used to
treat many inflammatory diseases in dogs. Cyclosporine inhibits calcineurin-dependent
pathways of T cell activation and resultant T cell cytokine production, and
glucocorticoids directly inhibit genes coding for cytokines. Little work has been done
comparing the effects of these agents on T cell cytokine production in dogs. Our study
measured T cell interleukin-2 (IL-2) and interferon-gamma (IFN-) production using
flow cytometry and T cell IL-2 and IFN- gene expression using quantitative reverse
transcription polymerase chain reaction (qRT-PCR) in activated canine T cells incubated
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with cyclosporine and dexamethasone in vitro. For flow cytometric assays, diluted whole
blood was cultured for 7 hours in the presence of cyclosporine (10, 100, 500, and 1000
ng/mL) or dexamethasone (10 ng/mL, 100 ng/mL, 1 μg/mL, and 10 μg/mL). For qRTPCR, whole blood was cultured for 5 hours with the same drugs at the same
concentrations, and RNA was then extracted from leukocytes. Flow cytometry and qRTPCR both demonstrated inhibition of IL-2 and IFN-γ that was concentration-dependent in
response to cyclosporine, and was more variable for dexamethasone. Quantitative RTPCR but not flow cytometry documented significant reduction of IL-2 expression after
dexamethasone treatment, while both methods showed concentration-dependent
suppression of IFN-γ. Quantitative RT-PCR also revealed additional cytokine
suppression at higher cyclosporine concentrations, an effect not found using flow
cytometry, and may therefore be the preferred method for cytokine determination in dogs.
Suppression of IL-2 and IFN-γ in activated T cells may have potential as an indicator of
the efficacy of cyclosporine and glucocorticoids in suppressing canine T cell function in
vivo, and may therefore be of value for characterizing the immunosuppression induced by
these drugs in clinical patients.
Introduction
Glucocorticoids and cyclosporine are commonly used as immunosuppressive
agents in both veterinary and human medicine. Glucocorticoids act through binding the
glucocorticoid receptor in cell cytoplasm, and then translocating to the nucleus to
modulate the activity of glucocorticoid response elements. Glucocorticoids alter the
expression of various cytokines and cell processes in lymphocytes and other immune
cells, and affect both innate and adaptive immune responses.1 Glucocorticoids also
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inhibit the transcription factors nuclear factor of kappa B (NF-κB) and activator protein 1
(AP-1), independent of their effects on glucocorticoid response elements.1 The primary
mechanism of action of cyclosporine is by inhibiting calcineurin, which in turn blocks
activation of the transcription factor nuclear factor of activated T cells (NFAT) and
decreases production of pro-inflammatory cytokines like IL-2, IL-4, IFN-γ, and tumor
necrosis factor-alpha (TNF-α).2,3 A combination of glucocorticoids and cyclosporine
leads to combined inhibition of NF-κB, AP-1, and NFAT, thereby blocking the three
transcription factors triggered after T cell receptor binding4 and causing an additive or
synergistic impact on T cell activity.5,6
Pharmacodynamic monitoring of levels of the cytokines produced by T cells has
been explored in human transplantation medicine as a means of identifying the biological
effects of a given immunosuppressive regimen on a patient. Pharmacodynamic
monitoring allows for individualized therapy, and such monitoring has been able to
associate very low cytokine expression with the potential for infection and malignancy,
and high residual T cell cytokine expression with inadequate immunosuppression and the
potential for transplant rejection.7-9 Immunologic assays are also beginning to be
explored in veterinary medicine to assess the effects of cyclosporine and other
immunosuppressant medications on lymphocyte responses in dogs and cats. Most of this
work has been done in in vitro drug incubation studies,10-14 but our laboratory has also
evaluated T cell cytokine production ex vivo in dogs taking oral cyclosporine.15,16
In human medicine, measurement of T cell production of NFAT-regulated
cytokines is considered useful for monitoring calcineurin inhibitor therapy after
transplantation, even in the presence of other co-administered immunosuppressive drugs.
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However, some of these other agents (especially glucocorticoids) are also known to affect
T cell cytokine expression, and could influence the results of pharmacodynamic assays.
In fact, glucocorticoid-mediated T cell suppression has been shown to be associated with
reduced cytokine levels, including reduced levels of IL-2.17 Since cyclosporine is
frequently used concurrently with glucocorticoids, it is important to determine what
effects glucocorticoids may have on any proposed biomarker assay used for
pharmacodynamic monitoring.
Different methods have been used for T cell cytokine evaluation in both animals
and humans, but few studies compare the results found with techniques reporting
different measures of cytokine expression, such as protein expression with flow
cytometry, and relative gene expression with quantitative RT-PCR. The authors are only
aware of one study comparing different measures of expression in the context of
immunosuppressive pharmacodynamics, which found the two methods of measurement
to provide comparable results in cynomolgus monkeys.18
The present study investigates the in vitro effects of exposure to cyclosporine and
dexamethasone on T cell cytokines measured using both flow cytometry and qRT-PCR in
a whole blood assay. Goals of this study were to explore the possible effects of
concurrent glucocorticoid administration on assays intended for cyclosporine monitoring
in dogs given cyclosporine, and to compare the responses of the two different measures
of cytokine expression across a range of drug concentrations. Samples from three dogs
were also used to determine the time of maximal cytokine expression after activation to
provide technique development information for subsequent drug effect studies.
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Materials and Methods
Animals
Six adult Walker hounds, determined to be healthy based on normal complete
blood count, serum biochemistry, urinalysis, and negative heartworm status, were used as
blood donors. They were housed in a university setting, and protocols approved by the
Institutional Animal Care and Use Committee (IACUC) were followed.
Reagents
Complete media (CM) was prepared as previously described.14 Phorbol 12myristate 13-acetate (PMA) and ionomycin were purchased from Sigma-Aldrich (St.
Louis, MO), and stock solutions of 1 mg/mL PMA and 1 mM ionomycin were made in
100% ethanol. Working solutions of cyclosporine (Bedford Laboratories, Bedford, OH)
and dexamethasone (Bimeda, Irwindale, CA) were prepared daily and diluted with
sodium chloride. Brefeldin A, the BD Cytofix/CytopermTM Plus Kit, and BD Pharm
LyseTM were purchased from Becton Dickinson (San Jose, CA).
Antibodies used for flow cytometry were: Fluorescein isothiocyanate (FITC)conjugated monoclonal anti-dog CD3 (MCA1774F, AbD Serotec, Raleigh, NC), Rphycoerythrin (R-PE)-conjugated monoclonal anti-bovine IFN-γ (MCA1783PE, AbD
Serotec), and biotinylated anti-canine IL-2 (BAF1815, R&D Systems, Minneapolis, MN).
RPE-conjugated streptavidin (#60669, Anaspec, San Jose, CA) was used as a secondary
label for IL-2. Isotype controls were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA).
For quantitative reverse transcription PCR (qRT-PCR), RNA was extracted using
a QIAamp® RNA Blood Mini Kit, and on-column DNase treatment was performed with
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the RNase-Free DNase Set, both from Qiagen (Valencia, CA). Assays were performed
using a SuperScript™ III Platinum® SYBR® Green One-Step qRT-PCR kit with Rox
used as a reference dye (Invitrogen, Carlsbad, CA).
Blood collection and stimulation
Blood was collected from the jugular vein into heparinized blood tubes. After
plating, samples were activated with 0.8 μM ionomycin and 12.5 ng/mL phorbol 12myristate 13-acetate (PMA). For flow cytometry, samples were diluted 1:9 with
complete media, and brefeldin A was added was added one hour after activation at a final
concentration of 1 μg/mL to stop cytokine secretion from T cells. For qRT-PCR analysis,
heparinized whole blood was used.
In vitro assays
Incubation study
Blood from 3 dogs was activated with PMA and ionomycin, and incubated at
37°C and 5% CO2 for 2, 4, 6, 8, 10 and 12 hours to determine the optimal time for
cytokine assessment. As described above, whole blood was used for qRT-PCR analysis,
and diluted whole blood samples for flow cytometry had brefeldin A added 1 hour after
starting the incubation.
Exposure to cyclosporine and dexamethasone
Prior to activation for the in vitro drug effect assessment, blood samples were
incubated with various concentrations of cyclosporine (10, 100, 500, and 1000 ng/mL)
and dexamethasone (10 ng/mL, 100 ng/mL, 1 μg/mL, and 10 μg/mL) for 1 hour.
Cyclosporine concentrations were based on previously established achievable blood
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concentrations after oral cyclosporine dosing, and concentrations found to suppress T cell
indices in vitro.10,15 Dexamethasone concentrations encompassed established typical
blood concentrations after oral dosing, and approached the higher concentrations tested
by Nafe and others.13,19,20 Based on results from the prior incubation study, samples were
then activated and incubated for five hours for qRT-PCR analysis, and seven hours for
flow cytometry. Brefeldin A was added one hour after activation for flow cytometry
samples. An untreated activated sample was also included, and unactivated samples were
run for each treatment condition as a control.
Flow cytometry
Flow cytometry was performed similarly to the previously published method,14
with modifications for a whole blood assay, as briefly described below. After incubation,
cells (350 uL per sample) were collected from the wells and immediately incubated with
FITC-conjugated anti-CD3 antibody for 25 minutes at room temperature (RT) in the
dark. Red blood cells were lysed using BD Pharm LyseTM according to the
manufacturer’s instructions. Following lysis, cells were washed and then fixed and
permeabilized using the BD Cytofix/CytopermTM Plus Kit as described previously.14-16
Samples were assayed using the FACSCaliburTM Flow Cytometer (Becton
Dickinson) and analyzed with CellQuestTM Pro software (Becton Dickinson).
Lymphocytes were identified using forward scatter and side scatter, and 10,000 events
were collected per sample. An additional gate was placed around CD3+ cells to include
T cells and exclude B cells. Cytokine staining was evaluated for CD3+ lymphocytes by
measuring mean fluorescence intensity (MFI) with single histogram statistics. Negative
controls included unactivated samples and isotype controls.
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RNA isolation and qRT-PCR analysis
After activation, total RNA was isolated from 1 mL heparinized whole blood as
previously described.21 Cytokine gene expression analysis was performed similarly to
the previously described method, with the modifications described below. Briefly, a 20
µL reaction volume was used with 30 ng template and 200 nM of each primer. Samples
were run on a StratageneTM Mx3005P Real-Time PCR system, and StratageneTM MxPro
QPCR software, version 4.10 (Agilent Technologies, Santa Clara, CA) was used for
analysis. Experimental samples were run in triplicate, with non-template controls run in
duplicate. Relative gene expression was calculated with mean Ct values using the 2-∆∆Ct
method, where: ΔΔCt = (CtGOI – Ctnorm)treated – (CtGOI – Ctnorm)untreated, and GOI is the gene
of interest (IL-2 and IFN-) and norm is the normalizer gene (GAPDH).22
Statistical analysis
Mean fluorescence intensity data were analyzed for flow cytometry, and the
percent reduction in cytokine gene expression relative to untreated sample expression
was evaluated for qRT-PCR. Following visual assessment of quantile-quantile plots of
the data (PROC UNIVARIATE, SAS for Windows 9.3, SAS Institute, Inc., Cary, NC,
USA), the data were judged to not be normally distributed. Consequently, nonparametric
methods of analysis that accounted for the hierarchical structure of the data were
utilized.23,24 For each outcome (flow cytometry: IL-2, IFN-; qRT-PCR: IL-2, IFN-),
the data were ranked and then analysis of variance type statistics were obtained through
PROC MIXED (SAS for Windows 9.3, SAS Institute, Inc., Cary, NC, USA) by using the
ANOVAF option and the MIVQUE0 estimation method for the covariance parameters
and a REPEATED statement specifying dog identity as the subject and an unstructured
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covariance structure. Either cyclosporine or dexamethasone concentration was included
in the models as a fixed effect. Differences in least square means with the SIMULATE
adjustment of P values were used for multiple comparisons of each of the four
concentration levels to the untreated sample. To allow method comparison using the
same outcome, percent reduction in cytokine expression relative to untreated levels was
calculated for flow cytometry to parallel the results found with qRT-PCR. The effect of
method (flow cytometry vs qRT-PCR), drug concentration, and their interaction on
percent reduction in cytokine expression was then assessed. A P value of less than 0.05
was considered to be significant for all analyses.
Results
Incubation study
Results of the blood sample incubation study are shown in Figure 4.1. For both
methods, cytokine production after PMA and ionomycin activation was similar for the
three dogs tested. For flow cytometry (Fig. 4.1 A and B), both IL-2 and IFN- MFI
increased to reach a maximum at either 6 or 8 hours, and then decreased with longer
testing intervals, except for 1 dog that had its highest IFN-γ level at 12 hours.
Quantitative RT-PCR results (Fig. 4.1 C and D) are shown as the ΔΔCt value between the
2, 4, 6, 8, 10, and 12-hour incubation value and unstimulated cytokine production.
Cytokine production increased substantially from 2 hours to 4 hours for both IL-2 and
IFN-γ, and mildly more at 6 hours, but remained at a similar expression level thereafter.
To allow the greatest potential to find a difference in expression and the most stable
expression level, the time cytokines reached an approximate maximum was selected.
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Seven hours of activation is recommended for flow cytometry, and five hours for qRTPCR. These incubation times were used in the following experiments.

Figure 4.1

Cytokine expression at various durations of activation with PMA plus
ionomycin

Cytokine expression measured using flow cytometry (A and B) in diluted whole blood,
and qRT-PCR (C and D) in whole blood after 2, 4, 6, 8, 10, and 12 hours of incubation
with 12.5 ng/mL PMA, and 0.8 μM ionomycin. Brefeldin A was added 1 hour after
activation for flow cytometry samples. Flow cytometry results are shown as the mean
fluorescence intensity for CD3-positive lymphocytes, and qRT-PCR results are shown as
the ΔΔCt value of stimulated-unstimulated cytokine values.
Cyclosporine and dexamethasone treatment
Cyclosporine caused a concentration-dependent decrease in IL-2 and IFN-γ
expression as measured with both flow cytometry and qRT-PCR (Figure 4.2). At 10
ng/mL cyclosporine, no significant difference was identified for either cytokine with
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either method relative to untreated control samples (P ≥ 0.21). By 100 ng/mL
cyclosporine, however, both IL-2 and IFN-γ expression were significantly reduced for
both methods (P ≤ 0.01). No additional suppression of cytokine production was noted at
higher concentrations of cyclosporine using flow cytometry (Fig. 4.2 A, P ≥ 0.16), while
significantly greater suppression of both cytokines was noted at 500 ng/mL than 100
ng/mL with qRT-PCR (Fig. 4.2 C, P ≤ 0.025). No additional suppression, however,
occurred with an increase to 1000 ng/mL (P ≥ 0.81).
For dexamethasone, results from flow cytometry and qRT-PCR were not as
closely related as they were for qRT-PCR. IL-2 was not significantly suppressed with
any dexamethasone concentration as measured by flow cytometry (Fig 4.2 B, P ≥ 0.095),
while qRT-PCR showed low but uniform significant reduction in gene expression at all
concentrations tested (Fig. 4.2 D, P ≤ 0.037). Suppression of IFN-γ was concentrationdependent after treatment with dexamethasone, and reached maximum levels at 100
ng/mL for both methods (Fig. 4.2 B and D). Dexamethasone caused more suppression
than cyclosporine at lower concentrations, but at higher concentrations, cyclosporine
caused a greater degree of cytokine suppression.
When considering the interaction between method and drug concentration on the
percent reduction in cytokine expression, there was no difference between flow
cytometry and qRT-PCR for cyclosporine at 10 or 100 ng/mL (P ≥ 0.29), while at 500
and 1000 ng/mL, qRT-PCR showed a significantly greater degree of suppression of both
IL-2 and IFN-γ than flow cytometry (P ≤ 0.01). For dexamethasone, 10 ng/mL and 10
μg/mL showed significantly greater suppression for IL-2 with qRT-PCR relative to flow
cytometry (P ≤ 0.028), and all drug concentrations were significantly different between
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the two methods for IFN-, reflecting the greater degree of suppression noted for qRTPCR versus flow cytometry (P ≤ 0.001).

Figure 4.2

Cytokine expression after in vitro exposure to varying concentrations of
cyclosporine and dexamethasone

Cytokine expression measured using flow cytometry (A and B) in diluted whole blood,
and qRT-PCR (C and D) in whole blood. Samples were activated with PMA and
ionomycin and incubated with cyclosporine (10, 100, 500, 1000 ng/mL) and
dexamethasone (10 ng/mL, 100 ng/mL, 1 μg/mL, 10 μg/mL). Flow cytometry results for
CD3-positive lymphocytes and qRT-PCR gene expression results are shown as the
percent expression relative to untreated samples. Letters are used to indicate significant
differences for IL-2, and numbers for IFN-γ. The presence of a letter/number indicates a
significant difference from untreated values, and treatments that do not share a
letter/number are significantly different (P < 0.05).
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Discussion
This study documents in vitro responses to exposure to two commonly used
immunosuppressive medications, cyclosporine and dexamethasone, using canine whole
blood assays. Both drugs are known to reduce the expression of pro-inflammatory
cytokines,25-28 and this effect was reflected in the present study. Both cyclosporine and
dexamethasone reduced the gene expression of IL-2 and IFN-γ. Cyclosporine caused
similar suppression of both cytokines, and caused a greater inhibition at high drug
concentrations than did dexamethasone. Dexamethasone, in contrast, caused greater
suppression of IFN-γ than IL-2. Flow cytometry was used to confirm effects on protein
production, and documented marked suppression of both IL-2 and IFN-γ for
cyclosporine, but only IFN-γ was significantly decreased after dexamethasone treatment.
While flow cytometry cytokine suppression plateaued at cyclosporine
concentrations greater than 100 ng/mL, qRT-PCR was notable in reflecting significantly
greater suppression at 500 ng/mL than 100 ng/mL. This is important because 100 ng/mL
is at the very low end of published target blood cyclosporine concentrations in dogs, and
concentrations higher than this are frequently achieved with oral drug dosing.29 Although
being sensitive to the effects of low drug concentrations is important for a biomarker, the
ability to discriminate greater degrees of immunosuppression at higher blood
concentrations is likely to further increase the utility of the assay, since the intent of the
assay is not only to document the effects of cyclosporine on T cells, but to also identify
patients with excessive immunosuppression that may be at risk of secondary infections.
In this study, a statistical comparison of the degree of reduction in marker
expression between flow cytometry and qRT-PCR was performed. Although the clinical
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consequences of decreased protein production relative to decreased gene expression
cannot be established, and an argument can be made that decreased protein expression is
ultimately the more relevant endpoint, the greater magnitude of reduction at higher drug
concentrations identified for cytokine gene expression compared to protein production is
potentially valuable from an analytical standpoint. Reductions of lesser magnitude are at
greater risk of being confounded by biological and analytical variability. In this sense,
the 90% decrease in gene expression identified at high cyclosporine concentrations is
appealing. Quantitative RT-PCR also carries the advantage of enabling storage of RNA
after extraction, thereby allowing samples collected on different days to be run on the
same plate to further reduce analytical variability.
One strength of the described techniques is the use of whole blood and diluted
whole blood assays. Cyclosporine is known to distribute into the different whole blood
components and to bind to non-target sites, and thus effective inhibitory drug
concentrations for pharmacodynamic measures are generally lower when tested in PBMC
than in whole blood, because in whole blood not as much free cyclosporine is available to
affect T cells. This effect can sometimes lead to marked differences in effective
inhibitory drug concentrations, as in the study by Batiuk and others that identified the
concentration of cyclosporine needed to cause 50% reduction in calcineurin activity
(IC50) as 2 ng/mL in peripheral blood leukocytes in culture medium versus 102 ng/mL for
peripheral blood leukocytes in whole blood, and an IC50 for IFN- production of 18
ng/mL in peripheral blood leukocytes in culture medium versus 690 ng/mL for peripheral
blood leukocytes in whole blood.30 Stein and others recognized this difference between
IC50 values for cyclosporine in isolated lymphocytes versus whole blood, and
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championed whole blood values as being more clinically relevant and reflective of trough
blood concentration targets in human transplant medicine, which are commonly 100-400
ng/mL.31 Other studies, however, have documented smaller differences based on sample
preparation, such as a cyclosporine IC50 for phytohemagglutinin-stimulated proliferation
of 345 ng/mL for PBMC and 384 ng/mL for whole blood.32 Separation of PBMC also
removes any drug present in plasma or red blood cells, which can impact assays that
require incubation. Because of these factors, results of in vitro incubation studies with
cyclosporine, especially when using isolated blood components rather than whole blood,
are sometimes of questionable biological relevance.
Most previous investigations of immunosuppressive drug effects in dogs and cats
have used peripheral blood mononuclear cells (PBMC).10,11,13 Density gradient isolation
of PBMC has been associated with variable effects on cytokine production in humans.
Using immunoassays, DeGroote and others reported increased IFN-γ and TNF-α in
whole blood versus PBMC, while IL-1 and IL-2 were higher in PBMC.33 Hӓrtel and
others reported increased IL-2, IL-4, and TNF-α mRNA expression in PBMC versus
whole blood, while IFN-γ levels were unchanged.34 Stordeur and others identified
increased IFN-γ mRNA in whole blood relative to PBMC, supporting the findings of
DeGroote, however, and suggested that rapid IFN- mRNA degradation at room
temperature may have influenced the findings of Hӓrtel.35
Although an insufficient number of drug concentrations were tested to precisely
identify the inhibitory concentration causing 50% reduction in cytokines (IC50) in this
study, cytokine suppression was already approximately 50% suppressed at 100 ng/mL
cyclosporine when measured using flow cytometry, and gene expression was
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approximately 55% of untreated levels at this concentration. Nafe and others reported an
IC50 for proliferation for cyclosporine of 15.8 ± 2.3 ng/mL in canine PBMC stimulated
with concanavalin A.13 Although an IC50 was not calculated, visual inspection of
cytokine mRNA expression plots by Kobayashi and others also suggest approximately
50% inhibition of IL-2, IL-4, and IFN-γ mRNA expression in canine PBMC treated with
10 ng/mL of cyclosporine.10 These data agree with the previously reported tendency for
IC50 values to be lower in PBMC than whole blood, but interestingly, the values are much
lower than most IC50 values for lymphocyte proliferation or cytokine expression in whole
blood or PBMC in humans. A study by Batiuk and others found IC50 values of less than
20 ng/mL for human leukocyte calcineurin inhibition and IFN- production in culture
medium,30 and studies by Hirano have documented very low IC50 values (< 10 ng/mL)
for blastogenesis by human PBMC,36,37 but most studies report cyclosporine IC50 values
of 200-500 ng/mL depending on the parameter studied.18,31,32,38,39 In cats, one study of
lymphocyte proliferation in whole blood documented an IC50 for cyclosporine of 55
ng/mL,12 while mRNA concentrations of IL-2, IL-4, and IFN-γ in feline PBMC were not
significantly inhibited by 50 ng/mL cyclosporine, but were more than 50% inhibited by
150 ng/mL cyclosporine.11
It is unclear whether the apparently greater lymphocyte responsiveness to
cyclosporine in veterinary species is due to differences in assay performance, or to
differences in species susceptibility to immunosuppressive effects. Genuine differences
in species T cell susceptibility to cyclosporine may have important clinical ramifications,
and could result from factors such as differences in cellular cyclophilin A levels,
calcineurin activity, or P-glycoprotein function. Published target blood cyclosporine
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concentrations are similar in dogs, cats, and humans, despite the fact that little work has
been done to correlate cyclosporine blood concentration with clinical response in
veterinary medicine. Several studies in dogs measured blood concentrations when
cyclosporine was used for dermatologic disease, and found poor correlations between
cyclosporine blood concentrations and clinical improvement in atopic dermatitis and anal
furunculosis.40,41 Cyclosporine is recognized to concentrate in the skin of dogs, however,
which may have affected these findings.42,43 Differences in T cell susceptibility could,
potentially, indicate a need for different target concentrations in dogs and cats than in
humans.
The immune-modulating effects of dexamethasone and other steroids have also
been investigated extensively in vitro. One study comparing the effects of cyclosporine
and methylprednisolone on human T cells documented that both cyclosporine and
methylprednisolone inhibited IL-2 expression to a greater extent than lymphocyte
proliferation, and reported an additive, but not synergistic, effect of the drugs in
combination.5 Other studies have documented cyclosporine to be less effective than
prednisolone at inhibiting whole blood lymphocyte proliferation, but noted a synergistic
effect when the drugs were used in combination.6,44 In contrast to cyclosporine, where
whole blood assays decrease the effective amount of cyclosporine at the target site,
higher proliferation IC50 values are noted for dexamethasone in PBMC relative to whole
blood,32 suggesting that assay effects are drug-dependent. Dexamethasone IC50 is
reported as 4.5 ng/mL in PBMC, and 3.5 ng/mL in whole blood. Lower IC50 values in
whole blood than PBMC are also reported for methylprednisolone and prednisolone.32
Another study reported dexamethasone at 39 ng/mL significantly inhibited PBMC
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proliferation in humans.45 In a study of lymphocyte proliferation by Nafe and others,
however, a much higher dexamethasone IC50 value of 1.36 ± 0.75 mg/mL (3460 ± 1900
μM) was reported for canine PBMC.13
In the present study, 10 ng/mL, 100 ng/mL, 1 μg/mL and 10 μg/mL
dexamethasone were tested. Uniform but fairly minimal suppression of IL-2 was
identified with qRT-PCR, while no effect on IL-2 production was identified with flow
cytometry. Dexamethasone induced greater suppression of IFN- compared to IL-2, and
suppression was concentration dependent with both methods of measuring cytokine
expression, but flow cytometry did not attain a 50% reduction in cytokine expression,
while gene expression results were less than 50% at all concentrations tested. Maximum
blood dexamethasone concentrations in dogs after 0.1 mg/kg of the drug is administered
intravenously ranged from 43 ng/mL to 297 ng/mL with an average of 118 ng/mL,20 and
averaged 571 ng/mL for dexamethasone in alcohol at 1 mg/kg intravenously.19 Typical
dexamethasone doses used clinically range from 0.1-0.3 mg/kg, so the concentrations
evaluated in this study include and exceed typical blood dexamethasone concentrations.
Although decreased expression of cytokines including IL-2 and IFN- is
recognized to be a primary and well-documented effect of glucocorticoids,25,28,46,47 recent
studies by two different groups documented a lack of effect of in vitro exposure to
methylprednisolone on human whole blood IL-2 mRNA expression,38 and of
methylprednisone on human whole blood IL-2 cytokine production by flow cytometry.48
Our study shows that cyclosporine causes a greater degree of T cell cytokine suppression
at high concentrations than dexamethasone, which is expected given the specific
mechanism of action of cyclosporine involves inhibition of NFAT-regulated cytokines.
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The minimal suppression of IL-2 following incubation with dexamethasone deserves
further study, however, and suggests that IL-2 has the potential to be a fairly specific
biomarker for cyclosporine in dogs receiving concurrent glucocorticoids.
In conclusion, this study provides an in vitro comparison of the effects of
cyclosporine and dexamethasone on whole blood T cell cytokine assays in dogs.
Cyclosporine caused concentration-dependent suppression of IL-2 and IFN-, with qRTPCR better able to detect additional suppression at higher drug concentrations.
Dexamethasone caused mild suppression of IL-2 as measured with qRT-PCR, but IL-2
levels were not significantly affected when measured by flow cytometry. In contrast,
dexamethasone did cause concentration-dependent suppression of IFN-, and produced a
significantly greater degree of suppression when measured by qRT-PCR compared to
flow cytometry. This study determined that optimal incubation times for cytokine
analysis in dogs are five hours with PMA and ionomycin for qRT-PCR, and seven hours
for flow cytometry. Further work is needed to determine the analytical method with the
greatest utility for reflecting the immunosuppression achieved by cyclosporine and
glucocorticoids in vivo, but our results suggest that cytokine monitoring may be a viable
method for monitoring the effects of immunosuppressive drugs in dogs.
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Abstract
The duration of immunosuppressive effects following oral cyclosporine in dogs is
unknown. This study used flow cytometry and quantitative reverse transcription–
polymerase chain reaction (qRT-PCR) to evaluate the effects of high-dose oral
cyclosporine across a 12-h dosing interval. Expression of interleukin-2 (IL-2) and
interferon-gamma (IFN-γ) was compared before and after 8 days of cyclosporine at 10
mg/kg every 12 h in six healthy dogs. Samples were collected at 0, 2, 4, and 8 h
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postdosing for analysis of unactivated and activated T-cell and whole blood cytokine
expression using flow cytometry and qRT-PCR, respectively, and at 0, 2, 4, 6, 8, and 10 h
postdosing for measurement of cyclosporine concentrations. Flow cytometry and qRTPCR both demonstrated significant marked reductions in IL-2 and IFN-γ levels at 0, 2, 4,
and 8 h after dosing compared to pretreatment levels (P < 0.05) for activated samples,
with less consistent effects observed for unactivated samples. Both flow cytometry and
qRT-PCR are viable techniques for measuring cyclosporine pharmacodynamics in dogs,
yielding comparable results with activated samples. Two hours postdrug administration is
the preferred time for concurrent assessment of peak drug concentration and cytokine
expression, and T-cell activation is needed for optimal results.
Introduction
Cyclosporine, a calcineurin inhibitor, is an important immunosuppressive agent in
both dogs and humans. A potent inhibitor of T-cell activation, cyclosporine decreases the
expression of nuclear factor of activated T-cell (NFAT) -regulated cytokines, including
interleukin-2 (IL-2), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNFα).1 Cyclosporine is commonly used in the treatment of inflammatory and immunemediated diseases in dogs, but there is substantial controversy regarding appropriate
dosage regimens and how to best assess response to therapy. Pharmacokinetic monitoring
is available, but there is limited information regarding appropriate therapeutic
cyclosporine blood concentrations for various disease states in dogs.2 Veterinarians
generally evaluate trough cyclosporine concentrations while, in human transplant
medicine, peak concentrations collected 2 h postdosing are better correlated with both
transplant rejection and the development of cyclosporine toxicity.3-7
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Blood cyclosporine concentrations in people do not predict patient response in all
situations, and much work in human medicine has therefore been directed at
pharmacodynamic monitoring of cyclosporine therapy.8-13 Pharmacodynamic studies of
cyclosporine typically involve assays of either calcineurin activity or lymphocyte
function. Lymphocyte proliferation, surface antigen expression, and cytokine production
have all been evaluated after cyclosporine therapy, with most work in veterinary
medicine focusing on reductions in peripheral blood and affected tissue cytokine levels.1417

Flow cytometry and quantitative reverse transcription–polymerase chain reaction

(qRT-PCR) are two commonly used techniques to measure T-cell cytokine responses, but
assess different outcomes. Flow cytometry measures actual protein levels, while qRTPCR looks only at messenger ribonucleic acid (mRNA) expression, which does not
necessarily correlate with protein production.
Previous work in our laboratory has both evaluated and validated techniques to
measure cytokine levels in dogs treated with cyclosporine using flow cytometry and qRTPCR.18-20 Our initial work demonstrated cyclosporine-mediated suppression of cytokines
and activation-related surface antigens for T cells incubated with cyclosporine,19 and
subsequent work confirmed that IL-2 and IFN-γ are suppressed after oral cyclosporine
administration in dogs.18 However, it has not been established if cyclosporine-mediated
suppression of NFAT-regulated cytokines is consistent across the dosing interval, or if
there is T cell recovery as the next dose is approached. This study evaluated the levels of
the cytokines IL-2 and IFN-γ measured using both flow cytometry and qRT-PCR across a
12-h oral cyclosporine dosing interval. Blood cyclosporine concentrations were also
measured. The goals of this study were to compare results obtained using both flow
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cytometry and qRT-PCR, and to determine the optimal time and method for
pharmacodynamic measurement of cyclosporine’s effects on T cells.
Material and Methods
Dogs
This project involved six healthy, purpose-bred, adult female Walker hounds.
Prior to the study, each dog received a physical examination, complete blood count,
serum biochemistry profile, urinalysis, fecal flotation, and heartworm testing, with no
significant abnormalities noted. Study protocols and animal care regimens were approved
by the Mississippi State University Institutional Animal Care and Use Committee.
Mississippi State University is accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care.
Cyclosporine administration
A repeated-measures design was used. Before drug administration, blood was
collected from all dogs for pretreatment evaluation of IL-2 and IFN-γ using both flow
cytometry and qRT-PCR. The dogs were divided into two groups of three dogs to
simplify sample processing. The first three dogs were then given oral microemulsified
cyclosporine (Atopica®, Elanco, Greenfield, IL, USA), at a dose of 10 mg/kg every 12 h
for 8 days. On day 8, blood was collected immediately prior to the next dose (0 h or
‘trough’ sample), and at two-hour intervals (2, 4, 6, 8, and 10 h) after drug
administration, for cyclosporine blood concentration determination. Additional blood was
collected predosing (0 h), and at 2, 4, and 8 h after dosing for cytokine analysis using
flow cytometry and qRT-PCR. Six days after the first three dogs began drug
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administration, the other three dogs began oral cyclosporine at the same dose and had
blood collected at the previously described time points after 8 days of treatment. All
blood was collected using jugular venipuncture with a 20-gauge needle and syringe, with
collected blood immediately transferred to heparinized vacutainers for cytokine
evaluation, and ethylenediaminetetraacetic acid (EDTA) tubes for cyclosporine blood
concentration determination.
Cyclosporine blood concentrations
Blood was collected into EDTA anticoagulant tubes, and shipped to the Auburn
University Veterinary Clinical Pharmacology Laboratory on ice for analysis within 48 h
of collection. Samples were thawed to room temperature and then mixed by inversion to
assure homogeneity. Cyclosporine was detected in canine EDTA whole blood using the
Siemens (New York, NY, USA) Cyclosporine Immunoassay® (CSA) and the Siemens
Cyclosporine Extended Range Immunoassay® (CSAE) on a Siemens (New York, NY,
USA) Dimension Xpand Plus® general chemistry analyzer. For CSA, the upper limit of
quantitation was 500 ng/mL, and the lower limit of quantitation was 25 ng/mL. CSA was
calibrated using the Siemens CSA Calibrator®, and quality control was performed using
More Diagnostics (Los Osos, CA, USA) RAP/TAC/CSA Controls®. For CSAE,
the upper limit of quantitation was 2000 ng/mL, and the lower limit of quantitation was
350 ng/mL, with the ability to dilute up to 6000 ng/mL. CSAE was calibrated with the
Siemens CSAE Calibrator®, and quality control was performed using More Diagnostics
Cyclosporine C2 Controls®.
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Cytokine analysis
Flow cytometry
Flow cytometric analysis was performed as previously described by our
laboratory,18,19 with modifications as described below. Antibodies used were as follows:
FITC-conjugated monoclonal anti-dog cluster of differentiation 3 (CD3) (MCA1774F,
AbD Serotec, Raleigh, NC, USA), RPE-conjugated monoclonal anti-bovine IFN-γ
(MCA1783PE, AbD Serotec), and biotinylated anti-canine IL-2 (BAF1815, R&D
Systems, Minneapolis, MN, USA). The secondary label for IL-2 was RPE-conjugated
streptavidin (#60669, Anaspec, San Jose, CA, USA). Heparinized blood was diluted with
complete media at a ratio of one part blood, nine parts media. Half of the diluted whole
blood samples were not activated (‘unactivated’), and the other half were activated with
12.5 ng/mL phorbol 12-myristate 13-acetate (PMA, cat. P8139) and 0.8 μM ionomycin
(cat. I0634), both purchased from Sigma-Aldrich (St. Louis, MO, USA). All samples
were then incubated for 7 h at 37°C in a 5% CO2 incubator. Brefeldin A (cat. 555029, BD
Biosciences, San Jose, CA, USA) was added 1 h after activation at a final concentration
of 1 μg/mL to stop cytokine secretion from T cells. After incubation, 350 μL of cell
suspension was collected per sample, and anti-CD3 monoclonal antibody was added
directly to the whole blood mixture and incubated for 25 min at room temperature in the
dark. Red blood cells were lysed with BD Pharm LyseTM (cat. 555899, BD Biosciences,
San Jose, CA, USA) as recommended by the manufacturer. Cells were then fixed and
permeabilized using the Becton Dickinson (BD) Cytofix/CytopermTM Plus Kit (cat.
554714, BD Biosciences, San Jose, CA, USA), stained for IL-2 and IFN-γ, and prepared
for flow cytometry as previously described.18,19
130

A BD FACSCaliburTM flow cytometer was used for staining evaluation, with data
analyzed using BD CellQuestTM Pro software (BD Biosciences, San Jose, CA, USA).
Lymphocytes were identified using forward scatter and side scatter, and 5000
lymphocytes were collected per sample. An additional gate identified CD3+ cells, and
cytokine expression was measured from cells within the lymphocyte and CD3+ gates.
Cell staining was measured using mean fluorescence intensity (MFI) values with single
histogram statistics, and isotype controls and unstained samples were used as negative
controls.
Quantitative RT-PCR
Heparinized whole blood was activated using 12.5 ng/mL PMA and 0.8 μM
ionomycin. Another set of blood samples was left unactivated, and all samples were
incubated for 5 h at 37°C and 5% CO2. Total RNA was extracted and qRT-PCR analysis
of IL-2 and IFN-γ expression performed as previously described by our laboratory,20 with
the minor modification of using 1.5 ng/μL RNA template in a 20 μL final reaction
volume. RNA was frozen at 80 °C until analysis, and samples from each dog were
analyzed on a single qPCR plate. Reactions were analyzed on a StratageneTM Mx3005P
using StratageneTM MxPro QPCR software v4.10 for analysis (Agilent Technologies,
Santa Clara, CA, USA).
Relative gene expression was assessed for threshold cycle (Ct) using the 2-ΔΔCt
method where ΔΔCt = (CtGOI - Ctnorm)treated - (CtGOI - Ctnorm)untreated, GOI is the gene of
interest, and norm is the reference gene (GAPDH).21
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Statistical analysis
A repeated-measures design was utilized in this study. Visual assessment of the
data using histograms with UNIVARIATE procedure of SAS® for Windows® 9.3 (SAS
Institute, Inc., Cary, NC, USA) indicated that the data were not normally distributed.
Consequently, the data were transformed by taking the reciprocal square root of each
value. Histograms indicated the transformed data were approximately normally
distributed. A separate mixed-effects model for each outcome was used to test for a time
effect using the MIXED procedure of SAS® for Windows® 9.3. A first-order
autoregressive covariance structure was specified in the repeated statement to
accommodate the repeated measures. For outcomes in which time had a significant effect
(P ≤ 0.05), comparisons were made between each pair of time points using differences in
least square means. Tukey Kramer adjustment was used for adjustment of P values for
the multiple comparisons. A P value of less than or equal to 0.05 was considered to be
significant for all analyses.
Results
Cyclosporine blood concentrations
Blood cyclosporine concentrations are presented in Fig. 5.1. After 8 days of
cyclosporine at 10 mg/kg every 12 h, peak concentrations were found at two hours
postdosing. At two hours postdosing, the range was 1944–5148 ng/mL, and the median
was 3040 ng/mL. Trough concentrations (0 h) ranged from 375 to 1021 ng/mL, with a
median of 701 ng/mL.
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Figure 5.1

Cyclosporine blood concentrations after 10 mg/kg oral dosing

Blood cyclosporine concentrations in six dogs measured on Day 8 after 7 days of oral
cyclosporine dosed at 10 mg/kg every 12 h. Each box represents the interquartile range
(IQR) from the 25th to 75th percentile. The point inside each box represents the median,
and whiskers extend to maximum and minimum values. Cyclosporine concentrations
were measured using an immunoassay.
Cytokine analysis
Flow cytometry
Flow cytometry results are shown in Figs 5.2 and 5.3. Activated sample
expression of IL-2 and IFN-γ was significantly reduced relative to pretreatment values at
0, 2, 4, and 8 h after dosing for both cytokines (P < 0.05). There was also significantly
reduced expression for the 2, 4, and 8 h samples relative to the 0 h (trough cyclosporine
blood concentration) sample for IFN-γ, and for the 8 h sample relative to the 0 h sample
for IL-2. All activated cyclosporine samples in all dogs at all post-treatment time points
showed markedly lower protein expression than pretreatment samples (Fig. 5.2).

133

Figure 5.2

Flow cytometry: Activated T-cell expression of IL-2 and IFN-γ

Activated T-cell expression of IL-2 (a) and IFN-γ (b) measured using flow cytometry in 6
dogs on Day 8 after oral cyclosporine dosing at 10 mg/kg every 12 h. Each box
represents the IQR. The point inside each box represents the median, and whiskers extend
to maximum and minimum values. Times that do not share a letter are significantly
different (P < 0.05) based on mixed model analysis of data transformed by taking the
reciprocal square root.
Unactivated sample analysis (Fig. 5.3) revealed significant reduction in IL-2
cytokine levels for hours 0, 2, 4, and 8 relative to pretreatment. IL-2 cytokine levels at
hour 8 were also significantly lower than at hours 0, 2, and 4. Only hours 2 and 8 were
significantly lower than pretreatment for IFN-γ levels, and hour 8 was also significantly
lower than hour 0. There was an overall smaller difference in MFI across the sampling
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times for unactivated samples than for activated samples, largely due to unactivated
pretreatment samples having much lower fluorescence than activated pretreatment
samples.

Figure 5.3

Flow cytometry: Unactivated T-cell expression of IL-2 and IFN-γ

Unactivated T-cell expression of IL-2 (a) and IFN-γ (b) measured using flow cytometry
in 6 dogs on Day 8 after oral cyclosporine dosing at 10 mg/kg every 12 h. Each box
represents the IQR. The point inside each box represents the median, and whiskers extend
to maximum and minimum values. Times that do not share a letter are significantly
different (P < 0.05) based on mixed model analysis of data transformed by taking the
reciprocal square root.
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Quantitative RT-PCR
Quantitative RT-PCR results are shown in Figs 5.4 and 5.5. Activated expression
of IL-2 and IFN-γ mRNA was significantly reduced relative to pretreatment values at 0,
2, 4, and 8 h after dosing for both cytokines (P < 0.05). In contrast to flow cytometry,
there was no statistically significant variation in the degree of suppression across the
dosing interval. All activated cyclosporine samples in all dogs at all post-treatment time
points showed markedly lower gene expression than pretreatment samples (Fig. 5.4).
There were no significant differences in mRNA expression for unactivated samples (Fig.
5.5).

136

Figure 5.4

Quantitative RT-PCR: Activated T-cell expression of IL-2 and IFN-γ

Activated whole blood mRNA expression of IL-2 (a) and IFN-γ (b) measured using qRTPCR in six dogs on Day 8 after oral cyclosporine dosing at 10 mg/kg every 12 h. Relative
quantification was performed using the 2-ΔΔCt method where Ct = (CtGOI - Ctnorm)treated (CtGOI - Ctnorm)untreated, GOI is the gene of interest, and norm is the reference gene
GAPDH. Data are expressed as a percentage of cytokine expression in pretreatment
samples, which are given a value of 100%. Each box represents the IQR. The point inside
each box represents the median, and whiskers extend to maximum and minimum values.
Times that do not share a letter are significantly different (P < 0.05) based on mixed
model analysis of data transformed by taking the reciprocal square root.
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Figure 5.5

Quantitative RT-PCR: Unactivated T-cell expression of IL-2 and IFN-γ

Unactivated whole blood mRNA expression of IL-2 (a) and IFN-γ (b) measured using
qRT-PCR in six dogs on Day 8 after oral cyclosporine dosing at 10 mg/kg every 12 h.
Relative quantification was performed using the 2-ΔΔCt method where Ct = (CtGOI Ctnorm)treated - (CtGOI - Ctnorm)untreated, GOI is the gene of interest, and norm is the reference
gene GAPDH. Data are expressed as a percentage of cytokine expression in pretreatment
samples, which are given a value of 100%. Each box represents the IQR. The point inside
each box represents the median, and whiskers extend to maximum and minimum values.
No significant differences identified.
Discussion
To the authors’ knowledge, this study provides the first paired evaluation of flow
cytometry and qRT-PCR for measurement of cyclosporine pharmacodynamics in dogs.
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Our results show that high-dose oral cyclosporine markedly and consistently suppresses
cytokine expression in healthy dogs in activated blood samples when evaluated using
either technique. Flow cytometry did show an extra degree of suppression of protein
expression at 2, 4, and 8 h relative to 0 h activated samples for IFN-γ, and a significant
difference between hour 0 and hour 8 for activated IL-2. Overall, however, there was
minimal variability seen in suppression across the oral dosing interval, and even at trough
drug concentrations 12 h after the previous oral cyclosporine dose (hour 0), both IL-2 and
IFN-γ were significantly reduced from pretreatment levels for activated samples using
both methods.
Unactivated cytokine expression showed similar findings as with activated
samples for flow cytometry, although differences in fluorescence were of smaller
magnitude. Activated samples had total separation of MFI values for pre- relative to
posttreatment samples, while unactivated fluorescence was lower and had overlap in preand post-treatment MFI values. The most prominent suppression was seen for 8-h
unactivated samples, which demonstrated significantly lower protein expression than all
other times for IL-2, and were lower than pretreatment and 0-h samples for IFN-γ.
Unactivated qRT-PCR samples, on the other hand, showed no significant differences
between pretreatment and post-treatment expression levels. Activation of lymphocytes
increases the production of cytokines, so lower expression and smaller differences among
treatment times were expected for unactivated samples. Testing unactivated samples
would decrease processing time, but because of the poorer separation in pre- and posttreatment cytokine levels, PMA and ionomycin activation of blood samples is
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recommended for pharmacodynamic evaluation of cyclosporine’s effects. The remainder
of this discussion will focus on activated cell expression results.
Previous work in our laboratory has evaluated both flow cytometry and qRT-PCR
for assessment of cyclosporine pharmacodynamics.18-20 Our earlier results suggested that
both techniques provide comparable results, and this study confirms that both methods
document similar marked suppression of T-cell function for an extended period after each
oral dose of cyclosporine. A previous study by Flores and others evaluated the ability of
flow cytometry and qRT-PCR to assess suppression of cytokine expression caused by in
vitro exposure to cyclosporine and tacrolimus in blood from cynomolgus monkeys and
concluded that both techniques could be used interchangeably when evaluating
cyclosporine pharmacodynamics in monkeys.22 Our study confirms that both methods
appear to be similarly interchangeable in dogs, at least at high drug doses.
The additional degree of cytokine protein suppression shown using flow
cytometry between trough drug concentrations and later time points in the dosing interval
suggests that this method may be more discriminating and able to reflect subtle
differences in suppression of T-cell function at high cyclosporine concentrations. As
suppression of cytokine mRNA expression in our study was slightly more rapid,
sustained and complete than protein expression, our results suggest that the qRT-PCR
assay may be more sensitive to the effects of cyclosporine and may therefore be able to
identify suppression of T-cell function at lower drug concentrations, but further studies at
lower cyclosporine concentrations would be needed to evaluate this possibility.
Blood cyclosporine concentrations following oral cyclosporine dosing in the
current study were similar to those reported in previous studies, with a peak at two hours
140

and a gradual reduction in blood concentrations over subsequent hours. Previously,
trough cyclosporine concentrations of 500 ng/mL have been suggested as a target for
attainment of adequate immunosuppression in dogs.23 However, although only four of the
six dogs in this study reached a 500 ng/mL trough concentration, with one dog attaining a
trough of only 375 ng/mL, all dogs showed marked suppression of cytokine expression.
Although ideal peak cyclosporine concentrations for dogs have not been published, a
target peak drug concentration of 800–1400 ng/mL is recommended by the Auburn
University Veterinary Clinical Pharmacology Laboratory for dogs, and all of the dogs in
the current study exceeded this level. In fact, the lowest peak in this study was 1944
ng/mL, and the median was 3040 ng/mL. Given the pronounced suppression of cytokines
in our study, our results suggest that, in dogs as in people, it is likely that peak
cyclosporine concentrations may correlate better with immunosuppressive effects
compared to trough concentrations. Although our study only looked at two cytokines and
therefore may not reflect all of the immune effects of cyclosporine, these two cytokines
are known to reflect the drug’s main mechanism of action.8
In human pharmacokinetic studies, cyclosporine area under the curve (AUC) has
been shown to have the best correlation with clinical outcome.24 Numerous studies have
confirmed the lack of correlation of trough cyclosporine concentrations with AUC and
clinical outcome and have identified improved outcomes when measuring peak drug
concentrations as a surrogate measure for AUC.3,4,25,26 In humans, cyclosporine
absorption occurs primarily in the first 4 h after oral administration, and drug absorption
exhibits high inter- and intra-individual variability that is not adequately reflected by
trough measurements.25 Temporally, calcineurin inhibition has been shown to closely
141

follow cyclosporine blood concentrations in humans and mice, with little residual
inhibition of calcineurin enzyme activity once blood drug concentrations drop below
peak levels.27 Interestingly, however, residual suppression of T-cell expression of NFATregulated cytokines can persist long beyond peak cyclosporine levels and the expected
parallel transient inhibition of calcineurin, as demonstrated by our study. The results of
our study, along with consideration of past studies, suggest that peak cyclosporine blood
concentrations determine the degree of calcineurin inhibition but that, even when blood
drug concentrations then drop markedly, the residual effects of transient calcineurin
inhibition on NFAT-regulated cytokine expression persist for a sustained period of time.
Pharmacodynamic monitoring of cytokine expression in dogs may therefore the best
means of determining both the extent and duration of suppression of T-cell function.
Further evaluation of cyclosporine pharmacokinetics and pharmacodynamics in dogs, and
correlation of results with clinical outcome in canine patients treated with cyclosporine, is
warranted.
One goal of the present study was to determine the ability of both flow cytometry
and qRT-PCR to detect differences in T-cell cytokine expression across the cyclosporine
dosing interval. Previous studies in human medicine used changes in cytokine expression
from trough to peak cyclosporine blood concentrations as indicators of the degree of
immunosuppression.13,28 Although flow cytometry did show mildly increased suppression
from trough to peak levels, overall the cytokine levels in our study were markedly
suppressed at all time points after cyclosporine administration, and there was minimal
change across the dosing interval. The high oral cyclosporine dose used in this study
most likely caused maximal immunosuppression without allowing time for immune
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recovery between doses. We chose a 10 mg/kg twice daily dose of oral cyclosporine for
this study because, based on our previous work, this dose tended to place trough drug
levels at or around the previously published target immunosuppressive concentration of
500 ng/mL.18,23 Lesser cyclosporine doses would be expected to cause more variation in
cytokine levels over time and, in fact, previous work in our laboratory confirmed that
when the much lower approved oral cyclosporine dose for canine atopic dermatitis (5
mg/kg once daily) was administered to healthy dogs, suppression of activated T-cell
cytokine expression 8 h after drug dosing in individual dogs varied from minimal to
marked.18 Based on studies in people, it is possible that marked suppression of T-cell
function at the time of peak cyclosporine blood concentrations with subsequent partial
recovery of suppression at the time of trough levels may be useful as an indicator of
adequate but not excessive immunosuppression13,28 and that the dose of cyclosporine
used in our study caused a greater degree of immunosuppression than might be needed
clinically. Further studies with various cyclosporine doses across the entire dosing
interval will be needed to determine whether the degree of suppression of T-cell function
varies postdosing in individual dogs at lower drug doses. For dogs on high doses of
cyclosporine, however, the results of our present study suggest that, using qRT-PCR,
cytokine analysis performed at any time point during therapy will likely reflect maximal
immunosuppression. For flow cytometry, however, samples 2–8 h postdosing may be
more representative.
To allow direct comparison with our previous work with cyclosporine, in which
effects were assessed after 1 week of drug therapy, we chose to monitor the effects of
cyclosporine on T-cell function after a full week of drug dosing, and our study confirmed
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that by this time cytokine expression was markedly suppressed. Undoubtedly, the
immunosuppressive effects of cyclosporine will begin to manifest before completion of a
full week of therapy, and further studies will be needed to determine how rapidly
suppression of T-cell cytokine expression occurs after drug therapy is commenced.
Our study has confirmed that at high drug doses expression of the cytokines IL-2
and IFN-γ is consistently reduced by cyclosporine, and suggests that, as in humans,
NFAT-regulated cytokine assays show great promise as biomarkers of drug-induced
immunosuppression. In human medicine, the information provided by pharmacokinetic
and pharmacodynamic monitoring is considered to be complementary, and the authors
suggest that utilization of both techniques will be needed to develop optimal
immunosuppressive regimens in canine patients.
Limitations of this study include the relatively small number of animals, the lack
of an untreated control group, the single dog breed (Walker hound) used, and the use of
only healthy animals. The sample size is typical for a standard pharmacokinetic study,29
and results were consistent among all dogs, with marked differences noted between
pretreatment and post-treatment results. A formal untreated control group was not
included, and provision of a control group would have confirmed a lack of diurnal effect.
However, a single untreated dog was included in the flow cytometry groups to ensure
appropriate sample activation at all times (data not shown). The Walker hound is not
known to have issues with cyclosporine metabolism or variations in activity of the efflux
pumps that handle drug metabolism and is expected to serve as an acceptable model for
all dog breeds. Cyclosporine is commonly used for inflammatory and immune-mediated
diseases, and it is possible that the presence of these conditions will affect cytokine
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responses to cyclosporine. As results from this study reflect healthy dogs only, further
work will be needed to confirm the relevance of these assays in diseased clinic patients.
In conclusion, our study describes the use of flow cytometry and qRT-PCR to
measure expression of the cytokines IL-2 and IFN-γ after oral cyclosporine
administration. Both techniques demonstrated marked reduction in activated cytokine
levels at 2, 4, 8 and 12 h after administration of high doses of cyclosporine, and the
degree of suppression of T-cell function varied only slightly across the 12-h dosing
interval. Unactivated sample results were more variable, especially for qRT-PCR. Based
on these results, pharmacodynamic monitoring of T-cell function could be performed
using PMA and ionomycin activation at any time point in the 12-h interval between drug
doses in dogs receiving chronic high-dose cyclosporine. Concurrent cyclosporine blood
concentration measurement revealed 12-h trough concentrations that, based on previous
studies, would be considered acceptable in only four of six dogs, but high (above
reference laboratory ‘target’ range) 2 h peak concentrations in all dogs. As peak drug
concentrations were attained in all dogs at 2 h postdosing, and cytokine expression was
also markedly suppressed in all dogs at 2 h postdosing, 2 h after administration of high
doses of cyclosporine is likely the most promising single time point for concurrent
pharmacokinetic and pharmacodynamic assessment, although further study is needed to
clarify the value of cytokine expression changes from trough to peak drug concentrations
at lower drug doses. Both flow cytometry and qRT-PCR provided similar information,
and our study suggests that both assays can be used interchangeably when monitoring
cyclosporine therapy, at least at high drug doses. Further studies at different cyclosporine
doses, and at earlier intervals after commencement of therapy, will be necessary to
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evaluate the full range of effects of the drug on T-cell function and to fully determine the
best technique for cytokine assessment.
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CONCLUSIONS AND FUTURE WORK
This dissertation describes initial investigations into pharmacodynamic assays of
the effects of cyclosporine in dogs. We showed that incubation with cyclosporine
inhibited the production of activation-related cytokines and surface antigens from canine
T cells in vitro using flow cytometry, and then modified this assay for whole blood. We
then investigated whole blood responses to in vitro incubation with cyclosporine and
dexamethasone across a range of concentrations, and identified concentration-dependent
suppression of IL-2 and IFN-γ after cyclosporine treatment with both flow cytometry and
qRT-PCR. Cytokine production was maximally suppressed at 100 ng/mL cyclosporine
by flow cytometry, and at 500 ng/mL cyclosporine by qRT-PCR. Dexamethasone caused
greater inhibition of IFN-γ than IL-2, and this effect was more pronounced when
measured with qRT-PCR than flow cytometry. Our final study investigated cytokine
expression by flow cytometry and qRT-PCR in dogs after high dose oral cyclosporine,
and documented uniform marked suppression of both IL-2 and IFN-γ gene expression
measured using qRT-PCR across a 12-hour dosing interval. For flow cytometry, samples
at the time of trough blood drug concentrations were significantly less suppressed than at
the time of peak concentrations and subsequent sampling times for IFN-, and the 8-hour
sample was significantly more suppressed than samples at trough blood concentrations
for IL-2. These results suggest that flow cytometry was able to reflect immune recovery
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as the next cyclosporine dose was reached. Unactivated samples were also evaluated in
this study, but no significant differences in gene expression following administration of
cyclosporine were found using qRT-PCR, and flow cytometry effects were less
pronounced and more variable compared to the effects observed when T cells were
activated. This confirms the need for activation of lymphocyte samples to enhance
cytokine production when evaluating cyclosporine pharmacodynamics.
The transition from PBMC to whole blood assays reflects an important
adjustment that preserves the effects of cyclosporine present in the plasma, and also more
closely mimics the environment in vivo. Chapters IV and V describe two comparisons of
qRT-PCR and flow cytometry with whole blood assays. Confirmation that gene
expression measured using qRT-PCR to a large extent parallels protein production
measured using flow cytometry is valuable. Our studies found similar results for both
methods, with the most notable difference being that IL-2 gene expression, but not
protein production, was significantly lower after in vitro incubation with dexamethasone.
It is interesting that while qRT-PCR seemed to be the more discriminating test, and more
able to reflect the effects of higher cyclosporine concentrations in vitro, in the ex vivo
study reported in Chapter V, flow cytometry but not qRT-PCR detected subtle
differences in cytokine levels across the oral dosing interval. This finding underscores
the need for confirmation of in vitro findings with subsequent oral dosing studies in dogs.
One limitation of our oral dosing study is that it was performed only in healthy
dogs. Concurrent disease has the potential to make cytokine levels more variable and to
influence patient drug disposition, and the influence of disease on the effects of
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cyclosporine deserve further investigation through pharmacokinetic/pharmacodynamic
correlation in clinic patients.
The original overall hypothesis of our research laboratory was that a
comprehensive panel of biomarkers of immunosuppression could be used to objectively
and accurately establish target doses and drug concentrations of cyclosporine in the dog.
Some biomarker panels for cyclosporine therapy have included lymphocyte proliferation,
surface antigen expression, and cytokine evaluation. While a larger panel does offer the
opportunity for more detailed and sensitive evaluation of the effects of an
immunosuppressive drug, the potential biomarkers evaluated in our studies were all
suppressed after exposure to cyclosporine, and all seemed to provide similar information.
For this reason, we elected to pursue the biomarkers that showed the most significant
suppression in response to cyclosporine, which, not surprisingly, were gene transcription
and protein production of NFAT-regulated cytokines.
In another study by our laboratory not described in this dissertation, both high
dose cyclosporine and the atopy cyclosporine dose of 5 mg/kg once daily were
investigated after oral dosing in dogs. This study showed that IL-2 and IFN-γ, but not IL4, were significantly decreased by high dose oral cyclosporine when measured using flow
cytometric evaluation of PBMC.1 Interferon-γ production was also significantly
decreased by the lower atopy dose of cyclosporine.1 These results, along with the studies
in this dissertation, suggested that IL-2 and IFN-γ were the best biomarkers for
monitoring the effects of cyclosporine in dogs, so we persisted with these markers in
subsequent studies. Although not as comprehensive as a full panel of biomarkers,
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limiting the number of biomarkers evaluated also makes application to clinic patients
more practical and cost-effective.
Our overall hypothesis also proposed that our biomarker assays could be used to
establish target drug concentrations and drug doses in dogs. This is an area where
substantial investigation is still needed. Chapter V describes the effects only of a single
high dose of cyclosporine and, as expected, biomarkers were dramatically suppressed.
The blood concentrations obtained in this study supported the comments of Dr. Dawn
Boothe, who suggested that achieving reliable peak cyclosporine concentrations is more
readily accomplished than attaining target trough concentrations.2 All of the dogs in this
study far exceeded Dr. Boothe’s target peak drug concentrations of 800-1400 ng/mL
(actual range 1944-5148 ng/mL), while only 5 of 6 dogs achieved minimum target trough
concentrations of 400-600 ng/mL, and only 3 dogs’ trough values exceeded this range.
Additional work at lower oral cyclosporine doses is needed to determine if cytokine
expression correlates better with peak or trough blood concentrations. Target blood
concentrations will also need to be critically evaluated based on cytokine expression and
clinical responses to best determine ideal dosing protocols for dogs. Based on our study,
the marked immunosuppression seen in all dogs suggests that reevaluation of at least
target blood trough concentrations is needed.
Another important consideration when suggesting adjusting dosing
recommendations for cyclosporine based on biomarker assays is the effect of concurrent
medications. Co-administered medications have the potential to influence cytokine
assays, and we did notice an effect, especially for IFN-γ, caused by exposure to
dexamethasone in vitro using our assays. Two other studies have reported no significant
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effect from in vitro exposure to either methylprednisone/methylprednisolone or
mycophenolic acid on T cell IL-2 production,3,4 and it may have been the short 2-4 hour
incubations in these studies that limited this interference. In clinic patients, determining
the individual effects of each drug on IL-2 or IFN-γ production may arguably be less
important, since the overall goal of combination drug therapy is greater reduction in T
lymphocyte and other immune cell responsiveness. Presently, however, it is important to
be able to determine the relative contribution of other drugs to biomarker suppression,
because the best optimization of cyclosporine therapy will include correlation with
clinical outcome in patients where additional immunosuppressive drugs are frequently
co-administered. Therefore, further investigation of our assays in dogs receiving multiple
immunosuppressant medications is needed.
The described work shows that our proposed biomarkers are successfully able to
reflect the effects of in vitro and orally administered cyclosporine and that, as expected,
cyclosporine causes reduction of T cell activation-related surface antigens and NFATregulated cytokines. Pharmacodynamic measures are intended to compliment the
information obtained from pharmacokinetic assays. Blood drug concentrations are still
needed to identify differences in drug absorption, and to determine the effects of drugs
that alter cyclosporine’s metabolism, such as ketoconazole. Although achieving a target
level of T cell suppression is encouraging, it is not yet known what level of suppression is
required for different diseases in veterinary medicine, or if a single target level will lead
to a consistent outcome among dogs. Therefore, for life-threatening immune-mediated
diseases and transplantation, attainment of target peak or trough blood concentrations
along with concurrent evaluation of cytokine function is suggested to provide as much
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information as possible to optimally individualize therapy. Once more studies are
performed correlating both pharmacokinetic and pharmacodynamic responses to clinical
outcomes, this recommendation may be able to be revisited for certain diseases. Based
on experience in human medicine, however, it is likely that dog pharmacodynamic
responses will be highly variable even with similar blood drug concentrations, thus
necessitating the continued performance of both types of assays.
Pharmacodynamic monitoring carries the advantage of avoiding several issues
associated with pharmacokinetic monitoring. By measuring effects on the final immune
target cell, the T cell, pharmacodynamic assays circumvent pharmacokinetic issues like
the relevance of free drug concentration in plasma versus total drug concentration, and
the influence of any biologically active metabolites. Pharmacodynamic assays also have
the potential to allow further investigation of the effects of the ABCB1 genotype and
variations in P-glycoprotein function on patient cyclosporine response. Mealey and
others showed that blood concentrations of cyclosporine and other P-glycoprotein
substrates were not affected by decreased P-glycoprotein expression. However, Mealey
and others also found that, at comparable blood concentrations of loperamide, Pglycoprotein deficient dogs were sedated while wild-type dogs were not, suggesting that
a deficiency of P-glycoprotein at the blood-brain barrier can lead to significant
differences in local drug effects at the level of the central nervous system.5 A similar
effect may exist for lymphocytes, which also utilize P-glycoprotein as an efflux pump to
expel cyclosporine from the cell cytoplasm. P-glycoprotein deficiency could lead to
decreased drug efflux from affected lymphocytes and greater immune suppression in
response to the same blood concentration of cyclosporine. Pharmacodynamic assays
155

have the ability to identify these target cell responses, and thereby provide important
clinical information with the potential to help explain individual patient variability to
cyclosporine.
Less certain is whether measuring circulating T cell responses is relevant for local
rather than systemic diseases, or for conditions affecting tissues where cyclosporine
concentrates, such as the skin. Cyclosporine may cause a local effect within the
gastrointestinal tract, for example and, as such, the effects of the drug on circulating T
cell responses may not be directly relevant to gastrointestinal effects. In contrast, the
opposite argument has been made for the use of cyclosporine in dogs with
meningoencephalomyelitis of unknown origin (MUE). Cyclosporine poorly crosses the
blood-brain barrier, but has still been found to be clinically effective for MUE. Adamo
and others suggest that inflammation may allow cyclosporine to cross the blood-brain
barrier or that, since autoimmune responses originate in peripheral lymphoid organs,
suppressing circulating T cell function may be sufficient to create a successful clinical
response.6 Further study is needed to correlate pharmacodynamic responses with clinical
outcome for different disease states.
The described cytokine assays are ready for immediate investigation in clinic
patients being treated with cyclosporine. Future investigations could also evaluate
cytokine responses at different drug doses to confirm the best assay for assessing
cyclosporine pharmacodynamics in dogs, and could also evaluate the effects of coadministered medications. These assays would also likely be useful to evaluate other
calcineurin inhibitors, such as tacrolimus. If it turns out, as is suggested in human
medicine, that suppression of NFAT-regulated cytokines is more reflective of the effects
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of cyclosporine than other immunosuppressive drugs, this will be helpful in the continued
clinical evaluation of cyclosporine in dogs. However, this would also raise the question
of what assays can be performed to evaluate the effects of other medications, and to
assess the overall immune status of the patient. Last, it will be important to understand
the effects of different disease states on baseline cytokine expression to be able to
effectively interpret patient responses to cyclosporine.
This dissertation describes preliminary work investigating cyclosporine
pharmacodynamics in dogs. Assay results are encouraging, and with further
investigation, cyclosporine pharmacodynamics may become an accepted method of
cyclosporine monitoring, with the ability to enhance the understanding of individual
patient immune responses to a potentially life-saving drug.
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